0001628280-23-017039.txt : 20230510 0001628280-23-017039.hdr.sgml : 20230510 20230510084930 ACCESSION NUMBER: 0001628280-23-017039 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230510 DATE AS OF CHANGE: 20230510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vericel Corp CENTRAL INDEX KEY: 0000887359 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943096597 STATE OF INCORPORATION: MI FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35280 FILM NUMBER: 23904508 BUSINESS ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7349305555 MAIL ADDRESS: STREET 1: 64 SIDNEY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AASTROM BIOSCIENCES INC DATE OF NAME CHANGE: 19960428 10-Q 1 vcel-20230331.htm 10-Q vcel-20230331
000088735912/312023Q1FALSEhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#ProductMemberhttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortizationhttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent00008873592023-01-012023-03-3100008873592023-04-30xbrli:shares00008873592023-03-31iso4217:USD00008873592022-12-3100008873592022-01-012022-03-31iso4217:USDxbrli:shares0000887359us-gaap:CommonStockMember2022-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000887359us-gaap:RetainedEarningsMember2022-12-310000887359us-gaap:RetainedEarningsMember2023-01-012023-03-310000887359us-gaap:CommonStockMember2023-01-012023-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000887359us-gaap:CommonStockMember2023-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000887359us-gaap:RetainedEarningsMember2023-03-310000887359us-gaap:CommonStockMember2021-12-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000887359us-gaap:RetainedEarningsMember2021-12-3100008873592021-12-310000887359us-gaap:RetainedEarningsMember2022-01-012022-03-310000887359us-gaap:CommonStockMember2022-01-012022-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310000887359us-gaap:CommonStockMember2022-03-310000887359us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310000887359us-gaap:RetainedEarningsMember2022-03-3100008873592022-03-31vcel:productvcel:segmentvcel:pharmacyxbrli:pure0000887359us-gaap:SubsequentEventMembervcel:MediWoundLtdMember2023-05-092023-05-090000887359us-gaap:FixedPriceContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2023-01-012023-03-310000887359us-gaap:FixedPriceContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2022-01-012022-03-310000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2023-01-012023-03-310000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:SalesChannelThroughIntermediaryMembervcel:ImplantsMember2022-01-012022-03-310000887359us-gaap:FixedPriceContractMembervcel:ProviderorFacilityMembervcel:ImplantsMember2023-01-012023-03-310000887359us-gaap:FixedPriceContractMembervcel:ProviderorFacilityMembervcel:ImplantsMember2022-01-012022-03-310000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2023-01-012023-03-310000887359us-gaap:TimeAndMaterialsContractMemberus-gaap:TimeAndMaterialsContractMembervcel:ImplantsMember2022-01-012022-03-310000887359vcel:BiopsyKitsMemberus-gaap:SalesChannelDirectlyToConsumerMember2023-01-012023-03-310000887359vcel:BiopsyKitsMemberus-gaap:SalesChannelDirectlyToConsumerMember2022-01-012022-03-310000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMemberus-gaap:AccountingStandardsUpdate201409Member2023-01-012023-03-310000887359us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMemberus-gaap:AccountingStandardsUpdate201409Member2022-01-012022-03-310000887359vcel:MACIImplantsAndKitsMember2023-01-012023-03-310000887359vcel:MACIImplantsAndKitsMember2022-01-012022-03-310000887359vcel:EpicelMemberus-gaap:SalesChannelDirectlyToConsumerMember2023-01-012023-03-310000887359vcel:EpicelMemberus-gaap:SalesChannelDirectlyToConsumerMember2022-01-012022-03-310000887359vcel:ProviderorFacilityMembervcel:NexoBridMember2023-01-012023-03-310000887359vcel:ProviderorFacilityMembervcel:NexoBridMember2022-01-012022-03-310000887359us-gaap:MachineryAndEquipmentMember2023-03-310000887359us-gaap:MachineryAndEquipmentMember2022-12-310000887359us-gaap:FurnitureAndFixturesMember2023-03-310000887359us-gaap:FurnitureAndFixturesMember2022-12-310000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2023-03-310000887359vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember2022-12-310000887359us-gaap:LeaseholdImprovementsMember2023-03-310000887359us-gaap:LeaseholdImprovementsMember2022-12-310000887359us-gaap:ConstructionInProgressMember2023-03-310000887359us-gaap:ConstructionInProgressMember2022-12-310000887359us-gaap:LicensingAgreementsMember2023-01-012023-03-310000887359us-gaap:LicensingAgreementsMember2022-01-012022-12-310000887359us-gaap:LicensingAgreementsMember2023-03-310000887359us-gaap:LicensingAgreementsMember2022-12-310000887359srt:MinimumMembervcel:AnnArborMichiganMember2023-01-012023-03-310000887359vcel:AnnArborMichiganMembersrt:MaximumMember2023-01-012023-03-310000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-28utr:sqft0000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-282022-01-28vcel:renewal_optioniso4217:USDutr:sqft0000887359srt:MinimumMembervcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-282022-01-280000887359srt:MaximumMembervcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-282022-01-280000887359vcel:A25NetworkDriveBurlingtonMassachusettsMember2022-01-012022-01-310000887359us-gaap:CommercialPaperMember2023-03-310000887359us-gaap:CorporateDebtSecuritiesMember2023-03-310000887359us-gaap:USGovernmentDebtSecuritiesMember2023-03-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-03-310000887359us-gaap:ShortTermInvestmentsMember2023-03-310000887359vcel:LongtermInvestmentsMember2023-03-310000887359us-gaap:CommercialPaperMember2022-12-310000887359us-gaap:CorporateDebtSecuritiesMember2022-12-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000887359us-gaap:ShortTermInvestmentsMember2022-12-310000887359vcel:LongtermInvestmentsMember2022-12-3100008873592022-01-012022-12-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000887359us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-03-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-03-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateNoteSecuritiesMember2023-03-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2023-03-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2022-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CorporateNoteSecuritiesMember2022-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateNoteSecuritiesMember2022-12-310000887359us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-03-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310000887359us-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000887359us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:CashAndCashEquivalentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310000887359us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-07-290000887359us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-07-292022-07-290000887359us-gaap:LetterOfCreditMemberus-gaap:LineOfCreditMember2022-07-290000887359us-gaap:LineOfCreditMember2022-07-290000887359us-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMember2022-07-292022-07-290000887359us-gaap:LineOfCreditMembersrt:MinimumMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMember2022-07-292022-07-290000887359us-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-07-292022-07-290000887359us-gaap:LineOfCreditMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMember2022-07-292022-07-290000887359us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:BaseRateMembersrt:MaximumMember2022-07-292022-07-290000887359us-gaap:LineOfCreditMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2022-07-292022-07-290000887359us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-07-292022-07-290000887359us-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-03-310000887359us-gaap:CostOfSalesMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-03-310000887359us-gaap:CostOfSalesMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-01-012022-03-310000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310000887359vcel:EmployeeStockAndEmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310000887359us-gaap:SellingGeneralAndAdministrativeExpensesMembervcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-03-310000887359us-gaap:SellingGeneralAndAdministrativeExpensesMembervcel:EmployeeStockAndEmployeeStockOptionMember2022-01-012022-03-310000887359vcel:EmployeeStockAndEmployeeStockOptionMember2023-01-012023-03-310000887359vcel:EmployeeStockAndEmployeeStockOptionMember2022-01-012022-03-310000887359us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000887359us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000887359us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000887359us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000887359us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000887359us-gaap:EmployeeStockOptionMember2022-01-012022-03-310000887359us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000887359us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310000887359vcel:MediWoundLtdMember2019-05-310000887359vcel:MediWoundLtdMember2023-02-280000887359vcel:MediWoundLtdMember2019-05-012019-05-310000887359us-gaap:SubsequentEventMembervcel:A25NetworkDriveBurlingtonMassachusettsMember2023-04-30



UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 Form 10-Q
 
☒      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
FOR THE QUARTERLY PERIOD ENDED: March 31, 2023 
or
☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 Commission File Number 001-35280
 
VERICEL CORPORATION
(Exact name of registrant as specified in its charter)
Michigan 94-3096597
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
 
64 Sidney Street
Cambridge, MA 02139
(Address of principal executive offices, including zip code) 

Registrant’s telephone number, including area code: (617) 588-5555 

 Securities registered pursuant to Section 12(b) of the Act: 
Title of ClassTrading Symbol(s)Name of Each Exchange on Which Registered
Common Stock (No par value)VCELNASDAQ

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes x No o
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes x No o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
 Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No x


As of April 30, 2023, 47,564,919 shares of Common Stock, no par value per share, were outstanding. 

1
VERICEL CORPORATION
 QUARTERLY REPORT ON FORM 10-Q
 TABLE OF CONTENTS
 
  Page
 PART I - FINANCIAL INFORMATION 
Item 1.
Financial Statements (Unaudited):
 
 
 
 
Item 2.
Item 3.
Item 4.
PART II — OTHER INFORMATION
Item 1.
Item 1A.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
2

PART I - FINANCIAL INFORMATION
 

Item 1. Financial Statements (Unaudited)

VERICEL CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, amounts in thousands)

 March 31,December 31,
 20232022
ASSETS  
Current assets:  
Cash and cash equivalents$61,834 $51,067 
Short-term investments57,442 68,471 
Accounts receivable (net of allowance for doubtful accounts of $47 and $47, respectively)
38,359 46,539 
Inventory15,370 15,986 
Other current assets4,540 4,803 
Total current assets177,545 186,866 
Property and equipment, net18,197 15,837 
Intangible assets, net7,344 7,500 
Right-of-use assets40,851 41,535 
Long-term investments19,910 19,962 
Other long-term assets1,249 1,303 
Total assets$265,096 $273,003 
LIABILITIES AND SHAREHOLDERS’ EQUITY  
Current liabilities:  
Accounts payable$11,125 $16,930 
Accrued expenses13,111 16,190 
Current portion of operating lease liabilities4,497 4,302 
Other current liabilities20 41 
Total current liabilities28,753 37,463 
Operating lease liabilities42,365 43,268 
Total liabilities71,118 80,731 
COMMITMENTS AND CONTINGENCIES (Note 12)
Shareholders’ equity:  
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,507 and 47,253, respectively
602,104 593,245 
Accumulated other comprehensive loss(636)(978)
Accumulated deficit(407,490)(399,995)
Total shareholders’ equity193,978 192,272 
Total liabilities and shareholders’ equity$265,096 $273,003 

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

3
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited, amounts in thousands, except per share amounts)
 
 Three Months Ended March 31,
 20232022
Product sales, net$41,017 $35,852 
Other revenue— 222 
Total revenue41,017 36,074 
Cost of product sales14,497 12,622 
Gross profit26,520 23,452 
Research and development5,212 4,860 
Selling, general and administrative29,485 25,865 
Total operating expenses34,697 30,725 
Loss from operations(8,177)(7,273)
Other income (expense):  
Interest income839 88 
Interest expense(145)(18)
Other (expense) income(12)112 
Total other income682 182 
Net loss$(7,495)$(7,091)
Net loss per common share:
Basic and diluted$(0.16)$(0.15)
Weighted-average common shares outstanding:
Basic and diluted47,387 46,985 

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

4
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited, amounts in thousands)

 Three Months Ended March 31,
 20232022
Net loss$(7,495)$(7,091)
Other comprehensive loss:
Unrealized gain (loss) on investments342 (459)
Comprehensive loss$(7,153)$(7,550)

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.

5
VERICEL CORPORATION 
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(Unaudited, amounts in thousands)

Common StockAccumulated Other Comprehensive Gain (Loss)Accumulated DeficitTotal Shareholders’ Equity
SharesAmount
BALANCE, DECEMBER 31, 202247,253 $593,245 $(978)$(399,995)$192,272 
Net loss— — — (7,495)(7,495)
Stock-based compensation expense— 8,731 — — 8,731 
Stock option exercises132 2,009 — — 2,009 
Shares issued under the Employee Stock Purchase Plan11 216 — — 216 
Issuance of stock for restricted stock unit vesting183 — — — — 
Restricted stock withheld for employee tax remittance(72)(2,097)— — (2,097)
Unrealized gain on investments— — 342 — 342 
BALANCE, MARCH 31, 202347,507 $602,104 $(636)$(407,490)$193,978 


Common StockAccumulated Other Comprehensive LossAccumulated DeficitTotal Shareholders’ Equity
SharesAmount
BALANCE, DECEMBER 31, 202146,880 $553,902 $(154)$(383,286)$170,462 
Net loss— — — (7,091)(7,091)
Stock-based compensation expense— 9,531 — — 9,531 
Stock option exercises125 1,155 — — 1,155 
Shares issued under the Employee Stock Purchase Plan9 310 — — 310 
Issuance of stock for restricted stock unit vesting108 — — — — 
Restricted stock withheld for employee tax remittance(41)(1,423)— — (1,423)
Unrealized loss on investments— — (459)— (459)
BALANCE, MARCH 31, 202247,081 $563,475 $(613)$(390,377)$172,485 

The accompanying notes to condensed consolidated financial statements are an integral part of these statements.


6

VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, amounts in thousands)

 Three months ended March 31,
 20232022
Operating activities:  
Net loss$(7,495)$(7,091)
Adjustments to reconcile net loss to net cash flows from operating activities:  
Depreciation and amortization expense1,158 873 
Stock-based compensation expense8,731 9,531 
Amortization of premiums and discounts on marketable securities(290)194 
Amortization of debt issuance costs54 — 
Non-cash lease costs1,112 1,076 
Other12 4 
Changes in operating assets and liabilities:  
Inventory616 (1,004)
Accounts receivable8,180 5,582 
Other current assets263 (847)
Accounts payable(274)(219)
Accrued expenses(3,079)(3,734)
Operating lease liabilities(1,128)(897)
Net cash provided by operating activities7,860 3,468 
Investing activities:  
Purchases of investments(9,787)(12,629)
Sales and maturities of investments21,500 5,041 
Expenditures for property and equipment(1,413)(3,081)
Purchases of intangible assets(7,500)— 
Net cash provided by (used in) investing activities2,800 (10,669)
Financing activities:  
Net proceeds from common stock issuance 2,225 1,465 
Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards(2,097)(943)
Other(21)(19)
Net cash provided by financing activities107 503 
Net increase (decrease) in cash, cash equivalents, and restricted cash10,767 (6,698)
Cash, cash equivalents, and restricted cash at beginning of period51,067 68,541 
Cash, cash equivalents, and restricted cash at end of period$61,834 $61,843 

7
VERICEL CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(Unaudited, amounts in thousands)


Three months ended March 31,
20232022
Supplemental disclosure of cash flow information:
Non-cash information:
Right-of-use asset and lease liability recognized$419 $— 
Additions to property and equipment included in accounts payable2,282 317 
Restricted stock held for employee tax remittance included in accounts payable— 480 

Three months ended March 31,
20232022
Reconciliation of amounts within the condensed consolidated balance sheets:
Cash and cash equivalents$61,834 $55,659 
Restricted cash— 6,184 
Total cash, cash equivalents, and restricted cash at end of period$61,834 $61,843 


The accompanying notes to condensed consolidated financial statements are an integral part of these statements.
8
VERICEL CORPORATION
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Organization

Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI®, Epicel® and NexoBrid®.

MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) to commercialize NexoBrid (anacaulase-bcdb) in North America. On December 28, 2022, the U.S. Food and Drug Administration (“FDA”) approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. The Company operates its business primarily in the U.S. in one reportable segment - the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific diseases.

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

COVID-19

In March 2020, the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-19”) to be a pandemic, which contributed to an economic downturn on a global scale, as well as significant volatility in the financial markets. At the time of the pandemic’s inception, and at times throughout its duration, there was significant volatility in the Company’s results of operations on a quarterly basis due to the widespread and periodic cancellation or delay of elective MACI surgical procedures throughout the U.S., staffing shortages and the Company’s ability to access customers. Based on declining COVID-related statistics, the U.S. Department of Health and Human Services has announced that the federal Public Health Emergency for COVID-19 is set to expire at the end of the day on May 11, 2023. Although at this juncture the pandemic’s effects on the Company’s business and results of operations have moderated, should a resurgence of COVID-19 occur it could result in additional disruptions that could impact the Company’s business and operations in the future, including intermittent restrictions on the ability of Company personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact its capacity to manufacture, sell and support the use of its products.

The War in Ukraine

The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.

9
Liquidity

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2023, the Company had an accumulated deficit of $407.5 million and had a net loss of $7.5 million during the three months ended March 31, 2023. The Company had cash and cash equivalents of $61.8 million and investments of $77.4 million as of March 31, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation (“FDIC”), the loss of which could have a negative effect on our operations and liquidity. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.

2. Basis of Presentation

The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.

The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses.

The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 23, 2023 (“Annual Report”).

Recent Accounting Pronouncements

No new accounting standards were adopted during the three months ended March 31, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.


10
3. Revenue

Revenue Recognition and Product Sales, Net

The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and NexoBrid following the five-step model in Accounting Standards Codification 606, Revenue Recognition.

MACI Biopsy Kits

MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.

MACI Implants

The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc. (“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration.

When the Company sells MACI the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of March 31, 2023. The total allowance for uncollectible consideration as of March 31, 2023 and December 31, 2022 was $7.1 million and $6.1 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the three months ended March 31, 2023.

Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year.


11
Epicel

The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital.

NexoBrid

The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020 the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA upon delivery, pursuant to this additional award.

Additionally, on December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.


12
Revenue by Product and Customer

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended March 31,
Revenue by product (in thousands) 20232022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)
$22,698 $15,190 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
3,485 3,369 
Implants sold direct based on contracted rates (c)
6,919 5,634 
Implants sold direct subject to third-party reimbursement (d)
501 861 
Biopsy kits - direct bill535 522 
Change in estimates related to prior periods (e)
52 419 
Total MACI implants and kits34,190 25,995 
Epicel
Direct bill (hospital)6,827 9,857 
NexoBrid revenue (f)
— 222 
Total revenue$41,017 $36,074 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).

4. Selected Balance Sheet Components

Inventory

Inventory consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Raw materials$14,264 $15,101 
Work-in-process1,043 832 
Finished goods63 53 
Total inventory$15,370 $15,986 


13
Property and Equipment

Property and Equipment, net consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Machinery and equipment$5,212 $5,041 
Furniture, fixtures and office equipment1,710 1,710 
Computer equipment and software8,208 8,224 
Leasehold improvements14,120 13,689 
Construction in process8,121 5,438 
Financing right-of-use lease28 37 
Total property and equipment, gross37,399 34,139 
Less accumulated depreciation(19,202)(18,302)
Total property and equipment, net$18,197 $15,837 

Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.0 million and $0.9 million, respectively.
 

14
Intangible Assets

Intangible assets, net consisted of the following:

March 31, 2023December 31, 2022
(In thousands)Useful Live (in years)Amortization MethodCostAccumulated AmortizationNetCostAccumulated AmortizationNet
NexoBrid license12Straight-line$7,500 $(156)$7,344 $7,500 $— $7,500 

Amortization expense for the three months ended March 31, 2023 was $0.2 million.

Future amortization expense of intangible assets as of March 31, 2023 is estimated to be as follows:

(In thousands)Amount
Remainder of 2023$469 
2024625 
2025625 
2026625 
2027625 
Thereafter4,375 
Total$7,344 

Accrued Expenses

Accrued Expenses consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Bonus related compensation$3,588 $7,132 
Employee related accruals2,739 3,101 
Insurance reimbursement-related liabilities5,769 5,030 
Other accrued expenses1,015 927 
Total accrued expenses$13,111 $16,190 


15
5. Leases

The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment.

With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000.

On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

The term of the Burlington Lease is currently expected to begin mid-year 2023 (the “Commencement Date”). The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million in total, following certain reductions to the tenant improvement allowance to account for the costs associated with changes to the landlord’s work on the Premises, as requested by the Company. The tenant improvement allowance will be used towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date.


16
In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three months ended March 31, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three months ended March 31, 2023 and 2022, the Company recognized $1.7 million of operating lease expense. For the three months ended March 31, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense.


Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationMarch 31, 2023December 31, 2022
Assets
OperatingRight-of-use assets$40,851 $41,535 
FinanceProperty and equipment, net28 37 
Total leased assets$40,879 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$4,497 $4,302 
FinanceOther current liabilities20 41 
Non-current
OperatingOperating lease liabilities$42,365 $43,268 
Total leased liabilities$46,882 $47,611 


17
6. Investments

Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:

March 31, 2023
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$14,306 $— $(48)$— $14,258 
Corporate notes43,157 — (559)— 42,598 
U.S. government securities4,920 5 — — 4,925 
U.S. government agency bonds15,600 — (29)— 15,571 
$77,983 $5 $(636)$— $77,352 
Classified as:
Short-term investments$57,442 
Long-term investments19,910 
$77,352 
December 31, 2022
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$15,707 $— $(101)$— $15,606 
Corporate notes52,159 — (831)— 51,328 
U.S. government agency bonds21,545 — (46)— 21,499 
$89,411 $— $(978)$— $88,433 
Classified as:
Short-term investments$68,471 
Long-term investments19,962 
$88,433 

As of March 31, 2023 and December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three months ended March 31, 2023 and 2022.


18
7. Fair Value Measurements

The Company’s fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2022 to March 31, 2023.

The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:

 March 31, 2023December 31, 2022
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$39,906 $39,906 $— $— $1,262 $1,262 $— $— 
Commercial paper14,258 — 14,258 — 15,606 — 15,606 — 
Corporate notes42,598 — 42,598 — 51,328 — 51,328 — 
U.S. government securities4,925 — 4,925 — — — — — 
U.S. government agency bonds (a)
15,571 — 15,571 — 27,976 — 27,976 — 
$117,258 $39,906 $77,352 $— $96,172 $1,262 $94,910 $— 

(a) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.

The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost which approximates fair value.

8. Revolving Credit Agreement

On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement.

Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio.

The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit
19
Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of March 31, 2023, there are no outstanding borrowings under the Revolving Credit Agreement.

The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement).

The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).

9. Stock-Based Compensation

The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (“Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.

Stock Compensation Expense

Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:
 Three Months Ended March 31,
(in thousands)20232022
Cost of product sales$885 $1,118 
Research and development977 1,350 
Selling, general and administrative6,869 7,063 
Total non-cash stock-based compensation expense$8,731 $9,531 

Service-Based Stock Options

During the three months ended March 31, 2023 and 2022, the Company granted service-based options to purchase common stock of 467,957 and 993,589, respectively. The weighted-average grant-date fair value of service-based options granted during the three months ended March 31, 2023 and 2022 was $18.00 and $20.99 per option, respectively.

Restricted Stock Units

During the three months ended March 31, 2023 and 2022, the Company granted 496,505 and 343,022 restricted stock units, respectively. The weighted-average grant-date fair value of restricted stock units granted during the three months ended March 31, 2023 and 2022 was $29.82 and $34.97 per unit, respectively.


20
10. Net Loss Per Common Share

A summary of net loss per common share is presented below:
 Three Months Ended March 31,
(Amounts in thousands, except per share amounts)20232022
Net loss$(7,495)$(7,091)
  
Basic weighted-average common shares outstanding47,387 46,985 
Effect of dilutive stock options and restricted stock units— — 
Diluted weighted-average common shares outstanding47,387 46,985 
Basic loss per common share$(0.16)$(0.15)
Diluted loss per common share$(0.16)$(0.15)
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options6,918 6,479 
Restricted stock units954 625 

11. NexoBrid License and Supply Agreements

On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological product, which was approved by the FDA on December 28, 2022 for commercial use in the U.S. NexoBrid contains proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.

Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.

In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. Pursuant to the terms of the license agreement, in February 2023, the Company tendered to MediWound a $7.5 million regulatory milestone payment following the FDA’s BLA approval of NexoBrid on December 28, 2022. The Company recorded the $7.5 million milestone payment for the licensing rights to commercially sell NexoBrid in the U.S., as an intangible asset (see Note 4, “Selected Balance Sheet Components” for further details).

The Company is additionally obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of March 31, 2023, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound will manufacture NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply.


21
Additionally, beginning in 2020 BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company has received a percentage of gross profit for sales directly to BARDA. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA, upon delivery, pursuant to this additional award.

12. Commitments and Contingencies

From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of March 31, 2023, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.

13. Subsequent Events

In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding into an escrow account maintained by the escrow agent a portion of its share of tenant improvement construction costs at the facility, which will be designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024. Additionally, and in order to support the expansion of the Company’s autologous cell manufacturing operations at the new facility in Burlington, the Company plans to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment.

22
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company and a leader in advanced therapies for the sports medicine and severe burn care markets. We currently market two U.S. Food and Drug Administration (“FDA”) approved autologous cell therapy products and one FDA-approved specialty biologic product in the U.S. MACI® is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® is a permanent skin replacement Humanitarian Use Device (“HUD”) for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). We also hold an exclusive license from MediWound Ltd. (“MediWound”) for North American rights to NexoBrid (anacaulase-bcdb). On December 28, 2022, the FDA approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. Following NexoBrid’s approval, we have begun cross-functional commercial launch activities for the product, including education, training and engagement activities and the deployment of additional NexoBrid account managers. The ultimate timing of the availability of commercial NexoBrid in the United States is dependent, in part, on MediWound’s completion of certain manufacturing updates required by the FDA in connection with the NexoBrid BLA approval. Based on MediWound’s current timeline to complete these activities, we now expect to receive U.S. commercial NexoBrid from MediWound and begin commercial sales during the third quarter of 2023.

COVID-19

In March 2020, the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-19”) to be a pandemic, which contributed to an economic downturn on a global scale, as well as significant volatility in the financial markets. At the time of the pandemic’s inception, and at times throughout its duration, there was significant volatility in our results of operations on a quarterly basis due to the widespread and periodic cancellation or delay of elective MACI surgical procedures throughout the U.S., staffing shortages and our ability to access customers. Based on declining COVID-related statistics, the U.S. Department of Health and Human Services has announced that the federal Public Health Emergency for COVID-19 is set to expire at the end of the day on May 11, 2023. Although at this juncture the pandemic’s effects on our business and results of operations have moderated, should a resurgence of COVID-19 occur it could result in additional disruptions that could impact our business and operations in the future, including intermittent restrictions on the ability of our personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact our capacity to manufacture, sell and support the use of our products.

The War in Ukraine

The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While we do not have operations in Russia or Ukraine and do not have exposure to distributors, or third-party service providers in Russia or Ukraine, we are unable to predict the ultimate impact that these actions will have on the global economy or on our financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.

Manufacturing

We have a cell manufacturing facility in Cambridge, Massachusetts, which is used for U.S. manufacturing and distribution of MACI and Epicel. The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel. Certain raw materials utilized in NexoBrid’s manufacture, including the supply of the active ingredient bromelain, are obtained from Taiwan.


23
Product Portfolio

Our marketed products include two FDA-approved autologous cell therapies: MACI, a third-generation autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel, a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent TBSA. Both autologous cell therapy products are currently manufactured and marketed in the U.S. Our product portfolio also includes a FDA-approved specialty biologic, NexoBrid, which is a topically-administered biological orphan product containing proteolytic enzymes that is indicated for eschar removal in adults with deep partial-thickness and/or full-thickness burns. We have entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. On December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. Following NexoBrid’s approval, we have begun cross-functional commercial launch activities for the product, including education, training and engagement activities and the deployment of additional NexoBrid account managers. The ultimate timing of the availability of commercial NexoBrid in the United States is dependent, in part, on MediWound’s completion of certain manufacturing updates required by the FDA in connection with the NexoBrid BLA approval. Based on MediWound’s current timeline to complete these activities, we now expect to receive U.S. commercial NexoBrid from MediWound and begin commercial sales during the third quarter of 2023.

MACI

MACI is a third-generation autologous chondrocyte implantation (“ACI”) product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.

Our target audiences are orthopedic surgeons who self-identify and/or have a formal specialty as sports medicine physicians, and a subpopulation of general orthopedic surgeons who perform a high volume of cartilage repair procedures. As of the date of this report, we employ approximately 75 MACI sales representatives to enable the sales force to reach our target audience. The team is divided into geographic regions, each managed by a Regional Manager and led by a Vice President of National MACI Sales. Most private payers have a medical policy that covers treatment with MACI with the top 30 largest commercial payers having a formal medical policy for MACI or ACI in general. With respect to private commercial payers that have not yet approved a medical policy for MACI, we often obtain approval on a case-by-case basis.

MACI is currently implanted into the patient’s cartilage defect through an open surgical procedure. We are currently evaluating the potential for the arthroscopic delivery of MACI to the cartilage defect – a procedure in which a surgeon can evaluate, prepare and treat the cartilage defect under direct vision using specialized instruments delivered through a number of smaller incisions or portals. The arthroscopic delivery of MACI could increase the ease of MACI’s use for physicians and reduce both the length of the procedure and a patient’s post-operative pain and recovery. We have designed and are currently developing novel and specialized instruments to be used in and help facilitate such a procedure. We have recently discussed with the FDA a non-clinical regulatory strategy to support the potential inclusion of arthroscopic delivery in MACI’s approved labeling. Specifically, following a Type C meeting with the FDA, we submitted a protocol for a MACI arthroscopic delivery human factors validation study and plan to initiate the study in the third quarter of 2023.

We also are evaluating the feasibility and potential market opportunity involved in delivering MACI treatment to patients suffering from cartilage damage in the ankle. We believe that this potential lifecycle enhancement and indication expansion for MACI will require conducting an additional randomized clinical trial concerning the product’s use in the ankle. Earlier this year, we conducted pre-IND interactions with the FDA concerning our clinical development program for MACI to treat cartilage injuries in the ankle, and based on feedback from the FDA, our team is actively working to finalize our non-clinical testing and propose a clinical development plan/protocol to FDA for review.

Epicel

Epicel is a permanent skin replacement for deep-dermal or full-thickness burns comprising greater than or equal to 30 percent TBSA. Epicel is regulated by the Center for Biologics Evaluation and Research (“CBER”) of the FDA under medical device authorities, and is the only FDA-approved cultured epidermal autograft product available for large total surface area burns in both adult and pediatric patients. Epicel was designated as a HUD in 1998 and a Humanitarian Device Exemption (“HDE”) application for the product was submitted in 1999. HUDs are devices that are intended for diseases or conditions that affect fewer than 8,000 individuals annually in the U.S. Under an HDE approval, a HUD cannot be sold for an amount that exceeds the cost of research and development, fabrication and distribution unless certain conditions are met. A HUD is eligible to be sold for profit after receiving HDE approval if the device meets certain eligibility criteria, including where the device is intended for the treatment of a disease or condition that occurs in pediatric patients and such device is labeled for use in pediatric patients. If the FDA determines that a HUD meets the eligibility criteria, the HUD is permitted to be sold for profit so
24
long as the number of devices distributed in any calendar year does not exceed the Annual Distribution Number (“ADN”). The ADN is defined as the number of devices reasonably needed to treat a population of 8,000 individuals per year in the U.S.

On February 18, 2016, the FDA approved our HDE supplement to revise the labeled indications of use for Epicel to specifically include pediatric patients. The revised product label also now specifies that the probable benefit of Epicel, mainly related to survival, was demonstrated in two Epicel clinical experience databases and a physician-sponsored study comparing outcomes in patients with large burns treated with Epicel relative to standard care. Because of the change in the label to specifically include use in pediatric patients, Epicel is no longer subject to the HDE profit restrictions. In conjunction with adding the pediatric labeling and meeting the pediatric eligibility criteria, the FDA has determined the ADN number for Epicel to be 360,400 which is approximately 40 times larger than the volume of grafts sold in 2022. As of March 31, 2023, our burn care field force was recently expanded to approximately 20 individuals to prepare for the launch of NexoBrid. The team is divided into geographic regions, each managed by a Regional Manager and led by a Vice President of National Burn Care Sales.

NexoBrid

Our portfolio of commercial-stage products now includes NexoBrid (anacaulase-bcdb), a topically-administered biological product containing proteolytic enzymes. The FDA approved NexoBrid on December 28, 2022, and the product is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. We have entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America.

NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets. NexoBrid has the potential to change the standard of care for eschar removal with respect to hospitalized burn patients and treat a significant addressable market in the U.S. With respect to NexoBrid, of the approximately 40,000 burn patients that are hospitalized in the U.S. each year, the majority, over 30,000, have thermal burns and will likely require some level of eschar removal. NexoBrid’s FDA approval expands our burn care franchise’s total addressable market, which will permit us to treat a significantly larger segment of hospitalized burn patients than with Epicel alone. The expansion of our target addressable market supports a broader commercial footprint, and we believe that this may help drive both increased NexoBrid use as well as increased Epicel awareness throughout the burn care space. With NexoBrid’s approval, our cross-functional commercial launch activities for the product are underway, including education, training and engagement activities and the deployment of additional NexoBrid account managers.

The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel. Certain raw materials utilized in NexoBrid’s manufacture, including the supply of the active ingredient bromelain are obtained from Taiwan. We expect to receive U.S. commercial product from MediWound and begin commercial sales of NexoBrid in the U.S. during the third quarter of 2023.

Results of Operations

The following is a summary of our condensed consolidated results of operations:
 Three Months Ended March 31,
(In thousands)20232022Change $Change %
Total revenue$41,017 $36,074 $4,943 13.7 %
Cost of product sales14,497 12,622 1,875 14.9 %
Gross profit26,520 23,452 3,068 13.1 %
Research and development5,212 4,860 352 7.2 %
Selling, general and administrative29,485 25,865 3,620 14.0 %
Total operating expenses34,697 30,725 3,972 12.9 %
Loss from operations(8,177)(7,273)(904)12.4 %
Total other income682 182 500 274.7 %
Net loss$(7,495)$(7,091)$(404)5.7 %

25

Comparison of the Periods Ended March 31, 2023 and 2022

Total Revenue

Revenue by product is as follows:

 Three Months Ended March 31,
(In thousands)20232022Change $Change %
MACI$34,190 $25,995 $8,195 31.5 %
Epicel6,827 9,857 (3,030)(30.7)%
NexoBrid— 222 (222)(100.0)%
Total revenue$41,017 $36,074 $4,943 13.7 %

Total revenue increase for the three months ended March 31, 2023 compared to the same period in 2022, was driven primarily by MACI volume and price growth, which more than offset lower Epicel volume and lower revenue associated with the delivery of NexoBrid to BARDA for emergency response preparedness.

Seasonality. Since March 2020, the effects of the COVID-19 pandemic have, at times, disrupted the normal seasonality of our MACI business. These previous effects have included periodic restrictions on the performance of elective surgical procedures throughout the country, the unavailability of physicians and/or changes to their treatment prioritizations, reductions in the levels of healthcare facility staffing and, in certain instances, the willingness or ability of patients to seek treatment and the inability of our sales representatives to call on surgeon customers. As a result of these effects, the MACI business seasonality in 2021 and 2020 did not follow our historic patterns. At this juncture the pandemic’s effects on our business and results of operations have moderated, although there continues to be a level of uncertainty whether MACI seasonality will return to pre-pandemic patterns. In the last five years through 2022, MACI sales volumes from the first through the fourth quarter on average represented 20% (18%-21% range), 21% (16%-24% range), 24% (21%-26% range) and 35% (33%-38% range) respectively, of total annual volumes. MACI orders are normally stronger in the fourth quarter due to several factors including the satisfaction by patients of insurance deductible limits and the time of year patients prefer to start rehabilitation. Due to the low incidence and variable occurrence of severe burns, Epicel revenue has inherent variability from quarter-to-quarter and does not exhibit significant seasonality.

Gross Profit

Gross profit increase for the three months ended March 31, 2023 compared to the same period in 2022, was driven by higher MACI volume and price growth, which more than offset higher employee costs, raw material price increases and higher external storage and manufacturing facility costs.

Research and Development Expenses

The following table summarizes research and development expenses, which include materials, professional fees and an allocation of employee-related salary and fringe benefit costs for our research and development projects:

 Three Months Ended March 31,
(In thousands)20232022Change $Change %
MACI$3,073 $2,989 $84 2.8 %
Epicel1,171 1,220 (49)(4.0)%
NexoBrid968 651 317 48.7 %
Total research and development expenses$5,212 $4,860 $352 7.2 %

Research and development expenses for the three months ended March 31, 2023 were $5.2 million, compared to $4.9 million for the same period in 2022. The increase is primarily due to lower reimbursement of expenses from MediWound related to NexoBrid BLA resubmission.


26
Selling, General and Administrative Expenses

Selling, general and administrative expenses for the three months ended March 31, 2023 were $29.5 million compared to $25.9 million for the same period in 2022. The increase in selling, general and administrative expenses was primarily due to higher headcount and employee expenses, additional travel and in-person events across the commercial organization, and an increase in marketing expenses.


27
Total Other Income 

The change in other income for the three months ended March 31, 2023, compared to the same period in 2022 was due primarily to fluctuations in the rates of return on our investments in various marketable debt securities slightly offset by interest expense related to our Revolving Credit Agreement.

Stock-based Compensation Expense

Non-cash stock-based compensation expense is summarized in the following table: 

 Three Months Ended March 31,
(In thousands)20232022Change $Change %
Cost of product sales$885 $1,118 $(233)(20.8)%
Research and development977 1,350 (373)(27.6)%
Selling, general and administrative6,869 7,063 (194)(2.7)%
Total non-cash stock-based compensation expense$8,731 $9,531 $(800)(8.4)%

The decrease in stock-based compensation expense for the three months ended March 31, 2023 compared to the same period in 2022, was due primarily to fluctuations in stock prices and the mix of service-based options and restricted stock units, which impacts the fair value of the options and restricted stock units awarded and the expense recognized in the period.

Liquidity and Capital Resources

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:

Three months ended March 31,
(In thousands)20232022
Net cash provided by operating activities$7,860 $3,468 
Net cash provided by (used in) investing activities2,800 (10,669)
Net cash provided by financing activities107 503 
Net increase (decrease) in cash, cash equivalents, and restricted cash$10,767 $(6,698)

Net Cash Provided by Operating Activities

Our cash and cash equivalents totaled $61.8 million, short-term investments totaled $57.4 million and long-term investments totaled $19.9 million as of March 31, 2023. The $7.9 million of cash provided by operations during the three months ended March 31, 2023 was primarily the result of non-cash charges of $8.7 million related to stock-based compensation expense, $1.1 million of operating lease amortization and $1.2 million in depreciation and amortization expense, offset by a net loss of $7.5 million and a net increase of $4.6 million related to movements in our working capital accounts. The overall increase in cash from our working capital accounts was primarily driven by a decrease in accounts receivable due to cash collections on the revenue from the seasonally-high previous sequential quarter, offset by a decrease in accounts payable and accrued expenses due to timing of payments.

Our cash, cash equivalents and restricted cash totaled $61.8 million, short-term investments totaled $44.9 million and long-term investments totaled $22.8 million as of March 31, 2022. The $3.5 million of cash provided by operations during the three months ended March 31, 2022 was primarily the result of non-cash charges of $9.5 million related to stock-based compensation expense, $1.1 million of operating lease amortization, $0.9 million in depreciation and amortization expense, offset by a net loss of $7.1 million and a net decrease of $1.1 million related to movements in our working capital accounts. The overall decrease in cash from our working capital accounts was primarily driven by a decrease in accounts payable and accrued expenses due to timing of payments, an increase in inventory due to increased production needs, offset by a decrease in accounts receivable due to a decrease in sales volume compared to the previous sequential quarter.


28
Net Cash Provided By (Used In) Investing Activities

Net cash provided by investing activities during the three months ended March 31, 2023 was the result of $21.5 million of investment sales and maturities, offset by $9.8 million in investment purchases, a $7.5 million regulatory milestone payment to MediWound resulting from the FDA’s approval of the NexoBrid BLA, and $1.4 million of property and equipment purchases primarily for manufacturing upgrades and construction in process related to the Burlington Lease.

Net cash used in investing activities during the three months ended March 31, 2022 was the result of $12.6 million in investments purchases and $3.1 million of property and equipment purchases primarily for manufacturing upgrades and leasehold improvements, offset by $5.0 million of investment sales and maturities.

Net Cash Provided by Financing Activities

Net cash provided by financing activities during the three months ended March 31, 2023 was the result of net proceeds from the exercise of stock options and the employee stock purchase plan of $2.2 million, partially offset by the payment of employee withholding taxes related to the vesting of restricted stock units of $2.1 million.

Net cash provided by financing activities during the three months ended March 31, 2022 was primarily the result of net proceeds from the exercise of stock options and the employee stock purchase plan of $1.5 million partially offset by payments of employee withholding taxes related to the vesting of restricted stock units of $0.9 million.

Liquidity

Since our acquisition of MACI and Epicel in 2014, our primary focus has been to invest in our existing commercial business with the goal of growing revenue. We have raised significant funds in order to advance and complete our product development and product life-cycle management programs and to market and commercialize our products, including NexoBrid. To date, we have financed our operations primarily through cash received through MACI and Epicel sales, debt, and public and private sales of our equity securities. We may finance our operations through the sales of equity securities, revolver borrowings or other debt financings, in addition to cash generated from operations.

We believe that our current cash on hand, cash equivalents, investments, and available borrowing capacity will be sufficient to support our current operations through at least 12 months from the issuance of the condensed consolidated financial statements included in this report. Although the effects of the ongoing COVID-19 pandemic have moderated in recent months, our business and operations may be adversely affected in the future if conditions were to worsen. Our actual cash requirements may differ from projections and will depend on many factors, including any future impacts of the COVID-19 pandemic, the level and pace of future research and development efforts, the scope and results of ongoing and potential clinical trials, the costs involved in filing, prosecuting and enforcing patents, the need for additional manufacturing capacity, competing technological and market developments, costs associated with possible acquisitions or development of complementary business activities, and the cost to market our products.

As of March 31, 2023, we were not party to any off-balance sheet arrangements.

Sources of Capital

On August 27, 2021, we entered into a Sales Agreement with SVB Securities, LLC (f/k/a SVB Leerink LLC), as sales agent (“SVB Securities”), pursuant to which we may offer and sell up to $200.0 million of shares of our common stock, no par value per share (“ATM Shares”). The ATM Shares to be offered and sold under the Sales Agreement will be issued and sold pursuant to an automatically effective shelf registration statement on Form S-3ASR (File No. 333-259119) filed by us on August 27, 2021, which expires three years from the filing date. We also filed a prospectus supplement relating to the offering and sale of the ATM Shares on August 27, 2021. We are not obligated to make any sales of ATM Shares, and SVB Securities is not required to sell any specific number or dollar amount of the ATM Shares under the Sales Agreement. As of March 31, 2023, we have sold no shares pursuant to the Sales Agreement.

On July 29, 2022, we entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). We have no immediate plans to borrow under the Revolving Credit Agreement, but we may use the facility for working capital needs and other general corporate purposes. As of March 31, 2023, there are no outstanding borrowings under the Revolving Credit Agreement, and we are in compliance with all applicable covenant
29
requirements. See Note 8, “Revolving Credit Agreement” in the accompanying condensed consolidated financial statements for further details.

Contractual Obligations and Commitments

The disclosure of our contractual obligations and commitments is set forth in the heading “Management’s Discussion and Analysis of Financial Conditions and Results of Operations - Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes, outside of the ordinary course of business, to our contractual obligations and commitments since December 31, 2022, except as noted below.

In April 2023, in connection with the Burlington Lease, we entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023 we began funding into an escrow account maintained by the escrow agent a portion of our share of tenant improvement construction costs at the facility, which will be designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, we have transferred into our escrow account 50% of our required cost amount, or approximately $28.3 million. We anticipate funding the remaining 50% of our required cost amount in late 2023 or early 2024. Additionally, and in order to support the expansion of our autologous cell manufacturing operations at the new facility in Burlington, we plan to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect our reported assets, liabilities, revenues, expenses, and related disclosures. Actual results may differ materially from these estimates under different assumptions and conditions.

There have been no material changes to our critical accounting policies and estimates in the three months ended March 31, 2023. For further information, refer to our summary of significant accounting policies and estimates in our Annual Report on Form 10-K filed for the year ended December 31, 2022.


Cautionary Note Regarding Forward-Looking Statements

This report, including the documents incorporated by reference herein, contains certain statements that describe our management’s beliefs concerning future business conditions, plans and prospects, growth opportunities and the outlook for our business based upon information currently available. Such statements are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”). Wherever possible, we have identified these forward-looking statements by words such as “will,” “may,” “anticipates,” “believes,” “intends,” “estimates,” “expects,” “plans,” “projects,” “trends,” “opportunity,” “current,” “intention,” “position,” “assume,” “potential,” “outlook,” “remain,” “continue,” “maintain,” “sustain,” “seek,” “target,” “achieve,” “continuing,” “ongoing,” and similar words or phrases, or future or conditional verbs such as “would,” “should,” “could,” “may,” or similar expressions. Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI®, Epicel®, and NexoBrid®, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely completion of a new headquarters and manufacturing facility in Burlington, Massachusetts, the ability to achieve or sustain profitability, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the arthroscopic delivery of MACI to the knee or the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, the ultimate timing of the commercial launch of NexoBrid in the United States, physician and burn center adoption of NexoBrid, supply chain disruptions or other events affecting MediWound Ltd.’s ability to manufacture and supply NexoBrid to meet customer demand, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine, adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, global geopolitical tensions or record inflation and the ongoing or future impacts of the COVID-19 pandemic on our business or the economy generally. These forward-looking statements are based upon assumptions our
30
management believes are reasonable. Such forward-looking statements are subject to risks and uncertainties, which could cause our actual results, performance and achievements to differ materially from those expressed in, or implied by, these statements, including, among others, the risks and uncertainties listed in our Annual Report under “Part I, Item 1A Risk Factors” and the risk listed in this Quarterly Report under “Part I, Item 1A Risk Factors.”

Because our forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change, actual results could be materially different and any or all of our forward-looking statements may turn out to be wrong. Forward-looking statements speak only as of the date made and can be affected by assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in our Annual Report on Form 10-K will be important in determining future results. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. Consequently, we cannot assure you that our expectations or forecasts expressed in such forward-looking statements will be achieved. Except as required by law, we undertake no obligation to publicly update any of our forward-looking or other statements, whether as a result of new information, future events, or otherwise.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

For quantitative and qualitative disclosures about market risk, see Part II, Item 7A. “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2022. Our exposures to market risk have not changed materially since December 31, 2022.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer (its Certifying Officers), evaluated the effectiveness of the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on the evaluation as of March 31, 2023, the Company’s Certifying Officers concluded that the Company’s disclosure controls and procedures were effective.

The Company has established disclosure controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Securities and Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, and that such information is accumulated and communicated to management of the Company, with the participation of its Certifying Officers, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

During the three months ended March 31, 2023, there were no material changes made in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act).


PART II - OTHER INFORMATION
Item 1. Legal Proceedings

We are currently not party to any material legal proceedings, although from time to time we may become involved in disputes in connection with the operation of our business.

Item 1A. Risk Factors

Factors that could cause the Company’s actual results to differ materially from those in this Quarterly Report are any of the risks described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on February 23, 2023. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations. As of the date of this Quarterly Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, except as follows.

31
Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, such as actual events or concerns involving liquidity, defaults or non-performance, could adversely affect our operations and liquidity.

Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds, have in the past and may in the future lead to market-wide liquidity problems.

We maintain cash and investments that are held in a number of investment and deposit accounts at leading financial institutions. The amounts held in the deposit accounts are in excess of the insurance coverage offered by the FDIC, and we may in the future, continue to have assets held at financial institutions that exceed the insurance coverage offered by the FDIC, the loss of which would have a severe negative effect on our operations and liquidity.

Uncertainty and liquidity concerns in the broader financial services industry remain. Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. The U.S. Department of Treasury, Federal Deposit Insurance Corporation (“FDIC”) and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments. However, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of banks or financial institutions in a timely fashion or at all.

Our access to our cash and cash equivalents in amounts adequate to finance our operations could be significantly impaired if the financial institutions with which we have arrangements directly face liquidity constraints or failures. In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any material decline in available funding or our ability to access our cash and cash equivalents could adversely impact our ability to meet our operating expenses, result in breaches of our contractual obligations or result in violations of federal or state wage and hour laws, any of which could have material adverse impacts on our operations and liquidity. Furthermore, should our customers have relationships with financial institutions that fail, this may result in a delay of collecting outstanding receivables, which could have a material adverse effect on our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

32
Item 6. Exhibits

The Exhibits listed in the Exhibit Index are filed as a part of this Quarterly Report on Form 10-Q.

EXHIBIT INDEX

Incorporated by Reference
Exhibit NumberDescription of ExhibitsFormFile NumberExhibitFiling Date
3.18-K000-220254.1December 17, 2009
3.2S-1333-1600443.2March 31, 2010
3.38-K000-220253.1March 25, 2011
3.48-K001-352803.1November 24, 2014
3.58-K000-220253.1November 12, 2010
4.110-K001-352804.5February 25, 2020
31.1*
31.2*
32.1*
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition Linkbase Document
104*

* Filed herewith.

33

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: May 10, 2023
 
 VERICEL CORPORATION
  
  
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
  
  
 /s/ JOSEPH A. MARA
 Joseph A. Mara
 Chief Financial Officer
 (Principal Financial Officer)


34
 EX-31.1 2 ex311ceocertificationq12023.htm EX-31.1 Document

EXHIBIT 31.1
 
CERTIFICATION
 
I, Dominick C. Colangelo, certify that:
 
1.                        I have reviewed this Quarterly Report on Form 10-Q of Vericel Corporation;
 
2.                        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3.                        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4.                        The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5.                        The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2023
 
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
 


 EX-31.2 3 ex312cfocertificationq12023.htm EX-31.2 Document

EXHIBIT 31.2
 
CERTIFICATION
 
I, Joseph A. Mara, certify that:
 
1. I have reviewed this Quarterly Report on Form 10-Q of Vericel Corporation;
 
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
 
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 10, 2023
 
 /s/ JOSEPH A. MARA
 Joseph A. Mara
 Chief Financial Officer
 (Principal Financial Officer)
 


 EX-32.1 4 ex321ceoandcfosoxcertifica.htm EX-32.1 Document

EXHIBIT 32.1
 
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Vericel Corporation (the “Company”) on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), the following:
 
(1)         The Report fully complies with the requirements of section 13(a) and 15(d) of the Securities Exchange Act of 1934; and
 
(2)         The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:  May 10, 2023
 
 /s/ DOMINICK C. COLANGELO
 Dominick C. Colangelo
 President and Chief Executive Officer
 (Principal Executive Officer)
 /s/ JOSEPH MARA
 Joseph Mara
 Chief Financial Officer
 (Principal Financial Officer)

 
A signed original of this written statement required by Section 906 has been provided to Vericel Corporation and will be retained by Vericel Corporation and furnished to the Securities and Exchange Commission or its staff upon request.


 EX-101.SCH 5 vcel-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Selected Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Revolving Credit Agreement link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Net Loss Per Common Share link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - NexoBrid License and Supply Agreements link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Selected Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Net Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Organization (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Selected Balance Sheet Components - Summary of inventory (Details) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Selected Balance Sheet Components - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Leases - Summary of assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Revolving Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Stock-Based Compensation - Expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Net Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - NexoBrid License and Supply Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vcel-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vcel-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 vcel-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Revenue, Product and Service [Extensible List] Revenue, Product and Service [Extensible Enumeration] Increase (Decrease) in Shareholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Related Party Transactions [Abstract] Related Party Transactions [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Sales threshold for first milestone License Agreement, Initial Milestone, Sales License Agreement, Initial Milestone, Sales Finance Finance Lease, Right-of-Use Asset, after Accumulated Amortization Area of real estate property Area of Real Estate Property Percent contributed to escrow account Escrow Deposit, Percent Contributed Escrow Deposit, Percent Contributed Unrealized gain (loss) on investments Unrealized gain (loss) on investment Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Total property and equipment, gross Property, Plant and Equipment, Gross Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Inventory: Inventory, Net [Abstract] Investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Financial Instruments [Domain] Financial Instruments [Domain] Basis spread on variable rate (in percent) Debt Instrument, Basis Spread on Variable Rate Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation Depreciation Number of specialty pharmacies Number of Contracted Specialty Pharmacies Number of Contracted Specialty Pharmacies Stock option exercises (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of stock for restricted stock unit vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Term of supply agreement License Agreement, Supply Agreement Term License Agreement, Supply Agreement Term Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Other Other Noncash Income (Expense) Property and equipment, net Total property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Leases Lessee, Finance Leases [Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Letter of credit cash deposit lease year three Letter Of Credit Cash Deposit Lease Year Three Letter Of Credit Cash Deposit Lease Year Three Equity Component [Domain] Equity Component [Domain] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Assets, fair value Assets, Fair Value Disclosure Leverage ratio Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Leases Lessee, Operating Leases [Text Block] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Estimated Fair Value Debt securities, fair value Debt Securities, Available-for-Sale Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Outstanding borrowings Long-Term Line of Credit Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Award Type [Axis] Award Type [Axis] Epicel Epicel [Member] Epicel [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Current portion of operating lease liabilities Operating Operating Lease, Liability, Current Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of fair value of securities, not including cash Debt Securities, Available-for-Sale [Table Text Block] Contract with Customer, Basis of Pricing [Axis] Contract with Customer, Basis of Pricing [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Corporate notes Corporate Note Securities [Member] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate by Type [Axis] Change in Accounting Estimate, Type [Domain] Change in Accounting Estimate, Type [Domain] Through Intermediary Sales Channel, Through Intermediary [Member] Total liabilities Liabilities Number of renewal options Lessee, Operating Lease, Number Of Renewal Options Lessee, Operating Lease, Number Of Renewal Options Stock-Based Compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Revolving credit facility Revolving Credit Facility [Member] Schedule of property and equipment, net Property, Plant and Equipment [Table Text Block] Document Type Document Type SOFR Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Revolving Credit Agreement Debt Disclosure [Text Block] Change in revenue recognized due to 0.5% change in uncollectible percentage Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount Product and Service [Domain] Product and Service [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Operating activities: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Rent start date, term Lessee, Lease Commencement, Rent Payment Start Date, Term Lessee, Lease Commencement, Rent Payment Start Date, Term Accrued expenses Increase (Decrease) in Accrued Liabilities Computer equipment and software Computer Equipment And Computer Software Intangible Asset [Member] Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks. Financial Instrument [Axis] Financial Instrument [Axis] Subsequent event Subsequent Event [Member] Document Period End Date Document Period End Date Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Total assets Assets Debt Disclosure [Abstract] Debt Disclosure [Abstract] Net loss per common share: Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Schedule of accrued expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accrued expenses Total accrued expenses Accrued Liabilities, Current Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Accounting Policies [Abstract] Employee related accruals Employee-related Liabilities, Current Line of credit Line of Credit [Member] Shareholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Net Loss Per Common Share Earnings Per Share [Text Block] Selected Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Short-term investments Short-Term Investments [Member] Award Type [Domain] Award Type [Domain] Schedule of finite-lived intangible assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Finished goods Inventory, Finished Goods, Gross Gross profit Gross Profit Basis of Presentation Basis of Accounting [Text Block] Financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Registrant Name Entity Registrant Name Renewal term of supply agreement License Agreement, Supply Agreement Renewal Term License Agreement, Supply Agreement Renewal Term Number of commercial-stage products Number Of Products Number Of Products Subsequent Events Subsequent Events [Text Block] Entity Address, City or Town Entity Address, City or Town Leases [Abstract] Leases [Abstract] Annual lease per square foot Lessee, Operating Lease, Annual Lease Per Square Foot Lessee, Operating Lease, Annual Lease Per Square Foot Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Axis] Minimum Minimum [Member] Operating lease liabilities Increase (Decrease) In Lease Liabilities Increase (Decrease) In Lease Liabilities Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Contract with Customer, Basis of Pricing [Domain] Contract with Customer, Basis of Pricing [Domain] Debt issuance costs, net Debt Issuance Costs, Net Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Adjustments for New Accounting Pronouncements [Axis] Accounting Standards Update [Axis] Fair Value Measurements Fair Value Disclosures [Text Block] Trading Symbol Trading Symbol Entity File Number Entity File Number 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Four Research and development Research and Development Expense Purchases of investments Payments to Acquire Short-Term Investments Marketable Securities [Line Items] Marketable Securities [Line Items] Restricted stock units granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units Restricted Stock Units (RSUs) [Member] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Other income (expense): Other Nonoperating Income (Expense) [Abstract] Insurance reimbursement-related liabilities Accrued Insurance, Current Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Raw materials Inventory, Raw Materials, Gross Accounts payable Increase (Decrease) in Accounts Payable Subsequent Events [Abstract] Subsequent Events [Abstract] Total revenue Revenues Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] 25 Network Drive, Burlington, Massachusetts 25 Network Drive, Burlington, Massachusetts [Member] 25 Network Drive, Burlington, Massachusetts Member Credit Facility [Domain] Credit Facility [Domain] Amortization of intangible assets Amortization of Intangible Assets Basic (in USD per share) Basic loss per common share (in USD per share) Earnings Per Share, Basic MACI implants and kits Implants [Member] Implants [Member] Counterparty Name [Domain] Counterparty Name [Domain] Total shareholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Right-of-use asset and lease liability recognized Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Credit Losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Entity Interactive Data Current Entity Interactive Data Current Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Net Income (Loss) Attributable to Parent [Abstract] Net Income (Loss) Attributable to Parent [Abstract] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Three Remaining percent to be contributed to escrow account Escrow Deposit, Remaining Percent To Be Contributed Escrow Deposit, Remaining Percent To Be Contributed Money market funds Money Market Funds [Member] Accumulated Deficit Retained Earnings [Member] Letter of credit cash deposit lease year six Letter Of Credit Cash Deposit Lease Year Four Letter Of Credit Cash Deposit Lease Year Four Common Stock Common Stock [Member] Schedule of non-cash stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Number of reportable segments Number of Reportable Segments Statement [Table] Statement [Table] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Document Quarterly Report Document Quarterly Report Monthly contractual lease payments Lessee, Operating Lease, Monthly Contractual Payments Lessee, Operating Lease, Monthly Contractual Payments Allowance for doubtful accounts Allowance for Credit Loss, Receivable, Other, Current Letter of credit Letter of Credit [Member] Furniture, fixtures and office equipment Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Operating lease liabilities Operating Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) NexoBrid NexoBrid [Member] NexoBrid Accounts receivable (net of allowance for doubtful accounts of $47 and $47, respectively) Accounts Receivable, after Allowance for Credit Loss, Current Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Equity Components [Axis] Equity Components [Axis] Recurring Fair Value, Recurring [Member] Tenant improvement allowance per square foot Lessee Operating Lease Tenant Improvement Allowance Per Square Foot Lessee Operating Lease Tenant Improvement Allowance Per Square Foot Document Fiscal Year Focus Document Fiscal Year Focus Remaining contractual maturity period Debt Securities, Available-for-sale, Contractual Maturity Period Debt Securities, Available-for-sale, Contractual Maturity Period Statement Statement [Line Items] Total other income Nonoperating Income (Expense) Variable Rate [Domain] Variable Rate [Domain] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Cost Finite-Lived Intangible Assets, Gross Selling, general and administrative Selling, General and Administrative Expense Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Right-of-use assets Operating Operating Lease, Right-of-Use Asset Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating lease expense Operating Lease, Expense Document Transition Report Document Transition Report Local Phone Number Local Phone Number Loss from operations Operating Income (Loss) Inventory Increase (Decrease) in Inventories Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Other accrued expenses Accrued Expenses, Other, Current Represents other accrued expenses, current. Ending balance (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Letter of credit cash deposit Letter Of Credit Cash Deposit Letter Of Credit Cash Deposit Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Name of Property [Domain] Name of Property [Domain] Annual lease base rent square subject to increase percentage Lessee, Operating Lease, Annual Lease Increase Limit, Percentage Lessee, Operating Lease, Annual Lease Increase Limit, Percentage Adjustments to reconcile net loss to net cash flows from operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration] Income Statement [Abstract] Income Statement [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Balance Sheet Location [Domain] Balance Sheet Location [Domain] Licensing Agreements Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Cost of product sales Cost of Goods and Services Sold Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Schedule of inventory Schedule of Inventory, Current [Table Text Block] Base rate Base Rate [Member] Short term investments Investments Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,507 and 47,253, respectively Common Stock, Value, Issued Increase option for leverage ratio Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum Weighted-average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Directly to consumer Sales Channel, Directly to Consumer [Member] Short-term lease costs (less than) Short-Term Lease, Cost Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Bonus related compensation Accrued Bonuses, Current Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Current Liabilities, Current [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Finance lease expense (less than) Finance Lease, Interest Expense Additions to property and equipment included in accounts payable Capital Expenditures Incurred but Not yet Paid Income Statement Location [Domain] Income Statement Location [Domain] Finance Finance Lease, Liability, Current Liabilities that are measured at fair value on a recurring basis Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Amendment Flag Amendment Flag Useful Live (in years) Finite-Lived Intangible Asset, Useful Life Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Shares issued under the Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Schedule of valuation of the company's investments and financial instruments that are measured at fair value on a recurring basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Construction in process Construction in Progress [Member] Entity Current Reporting Status Entity Current Reporting Status Other current liabilities Other Liabilities, Current Other long-term assets Other Assets, Noncurrent Depreciation and amortization expense Depreciation, Depletion and Amortization Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Term of contract Lessee, Operating Lease, Term of Contract Shares issued under the Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Counterparty Name [Axis] Counterparty Name [Axis] Schedule of assets and liabilities Assets And Liabilities, Leases [Table Text Block] Assets And Liabilities, Leases [Table Text Block] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Liabilities Liabilities [Abstract] Schedule of finite-lived intangible assets, future amortization expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Stock options Share-Based Payment Arrangement, Option [Member] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Contract rate Fixed-Price Contract [Member] Stock option exercises Stock Issued During Period, Value, Stock Options Exercised Other (expense) income Other Nonoperating Income (Expense) Classified as: Balance Sheet Location [Axis] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total operating expenses Operating Expenses Maximum Maximum [Member] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Work-in-process Inventory, Work in Process, Gross Total current assets Assets, Current Entity Small Business Entity Small Business Measurement Frequency [Domain] Measurement Frequency [Domain] Non-cash lease costs Operating Lease, Right-of-Use Asset, Amortization Expense Total leased assets Right Of Use Asset Right Of Use Asset Intangible assets, net Total Finite-Lived Intangible Assets, Net Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Title of 12(b) Security Title of 12(b) Security Short-term investments Short-Term Investments Subsequent Event [Line Items] Subsequent Event [Line Items] Debt Instrument [Line Items] Debt Instrument [Line Items] Lease option to extend term Lease Option To Extend Term Lease Option To Extend Term Total leased liabilities Lease Liability Noncurrent Lease Liability Noncurrent U.S. government agency bonds US Government Agencies Debt Securities [Member] Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments Selling, general and administrative Selling, General and Administrative Expenses [Member] Investments, Debt and Equity Securities [Abstract] 2025 Finite-Lived Intangible Asset, Expected Amortization, Year Two LIABILITIES AND SHAREHOLDERS’ EQUITY Liabilities and Equity [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Purchases of intangible assets Payments to Acquire Intangible Assets Weighted-average common shares outstanding: Anti-dilutive shares excluded from diluted net loss per common share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Inventory Total inventory Inventory, Net Change in estimate of uncollectible (percent) Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage Change in estimates related to prior periods Change in Accounting Method Accounted for as Change in Estimate [Member] Accounts payable Accounts Payable, Current Less accumulated depreciation Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization Organization Nature of Operations [Text Block] Restricted stock held for employee tax remittance included in accounts payable Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable Entity Filer Category Entity Filer Category Net proceeds from common stock issuance Proceeds from Issuance of Common Stock Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Accrued expenses Accrued Liabilities, Current [Abstract] Total non-cash stock-based compensation expense Share-Based Payment Arrangement, Expense COMMITMENTS AND CONTINGENCIES (Note 12) Commitments and Contingencies Security Exchange Name Security Exchange Name Issuance of letters of credit Letters of Credit Outstanding, Amount Property and equipment, net: Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Product sales, net Revenue from Contract with Customer, Excluding Assessed Tax Cash and cash equivalents Cash and Cash Equivalents [Member] Non-current Liabilities, Noncurrent [Abstract] Cover [Abstract] Cover [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Long-term investments Debt Securities, Available-for-Sale, Noncurrent Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Revenue Revenue from Contract with Customer [Text Block] U.S. government securities US Government Debt Securities [Member] Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and shareholders’ equity Liabilities and Equity Debt instrument, term Debt Instrument, Term Cost, Product and Service [Extensible List] Cost, Product and Service [Extensible Enumeration] Amortization of debt issuance costs Amortization of Debt Issuance Costs Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Ann Arbor Michigan Ann Arbor, Michigan [Member] Ann Arbor, Michigan Effect of dilutive stock options and restricted stock units (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Accounts receivable Increase (Decrease) in Receivables Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Biopsy kits Biopsy Kits [Member] Biopsy Kits [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Diluted (in USD per share) Diluted loss per common share (in USD per share) Earnings Per Share, Diluted Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Financing right-of-use lease Finance Lease, Right-of-Use Asset, before Accumulated Amortization Other current assets Other Assets, Current Additional funding License Agreement, Additional Funding License Agreement, Additional Funding Maximum contingent consideration License Agreement, Contingent Consideration, Maximum License Agreement, Contingent Consideration, Maximum Marketable Securities [Table] Marketable Securities [Table] Corporate notes Corporate Debt Securities [Member] Tenant improvement allowance Lessee, Operating Lease, Tenant Improvement Allowance Lessee, Operating Lease, Tenant Improvement Allowance Line of credit facility, commitment fee (in percent) Line of Credit Facility, Commitment Fee Percentage MediWound Ltd MediWound Ltd [Member] MediWound Ltd [Member] Sales and maturities of investments Proceeds from Sale, Maturity and Collection of Short-Term Investments Entity Address, Address Line One Entity Address, Address Line One Other Proceeds from (Payments for) Other Financing Activities Product and Service [Axis] Product and Service [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Employee stock purchase plan and service-based stock options Employee Stock And Employee Stock Option [Member] Employee Stock And Employee Stock Option [Member] Interest expense Interest Expense Long-term investments Long-term Investments [Member] Long-term Investments [Member] Credit Facility [Axis] Credit Facility [Axis] Time-and-materials contract Time-and-Materials Contract [Member] Reconciliation of amounts within the condensed consolidated balance sheets: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Machinery and equipment Machinery and Equipment [Member] Subsequent Event [Table] Subsequent Event [Table] Entity Tax Identification Number Entity Tax Identification Number M A C I Implants and kits MACI Implants And Kits [Member] MACI Implants And Kits Schedule of disaggregation of revenue Disaggregation of Revenue [Table Text Block] Remainder of 2023 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Contingent consideration License Agreement, Contingent Consideration License Agreement, Contingent Consideration Restricted stock withheld for employee tax remittance (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Total property and equipment, gross Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization Other revenue NexoBrid revenue Revenue Not from Contract with Customer, Other Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Consideration payment for license License Agreement, Consideration License Agreement, Consideration Interest income Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Name of Property [Axis] Name of Property [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Restricted stock withheld for employee tax remittance Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Provider or Facility Provider or Facility [Member] Provider or Facility [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Type of Adoption [Domain] Accounting Standards Update [Domain] City Area Code City Area Code ASSETS Assets Assets [Abstract] Other current assets Increase (Decrease) in Other Current Assets Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] NexoBrid License and Supply Agreements License Agreement [Text Block] License Agreement [Text Block] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted average grant-date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Variable Rate [Axis] Variable Rate [Axis] Impairments of assets Asset Impairment Charges Expenditures for property and equipment Payments to Acquire Property, Plant, and Equipment Escrow deposit amount Escrow Deposit Research and development Research and Development Expense [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] 2024 Finite-Lived Intangible Asset, Expected Amortization, Year One Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of product sales Cost of Sales [Member] Contract with Customer, Sales Channel [Domain] Contract with Customer, Sales Channel [Domain] Product [Member] EX-101.PRE 9 vcel-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - shares
 3 Months Ended
Mar. 31, 2023
Apr. 30, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-35280  
Entity Registrant Name VERICEL CORPORATION  
Entity Incorporation, State or Country Code MI  
Entity Tax Identification Number 94-3096597  
Entity Address, Address Line One 64 Sidney Street  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02139  
City Area Code 617  
Local Phone Number 588-5555  
Title of 12(b) Security Common Stock (No par value)  
Trading Symbol VCEL  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   47,564,919
Entity Central Index Key 0000887359  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 61,834 $ 51,067
Short-term investments 57,442 68,471
Accounts receivable (net of allowance for doubtful accounts of $47 and $47, respectively) 38,359 46,539
Inventory 15,370 15,986
Other current assets 4,540 4,803
Total current assets 177,545 186,866
Property and equipment, net 18,197 15,837
Intangible assets, net 7,344 7,500
Right-of-use assets 40,851 41,535
Long-term investments 19,910 19,962
Other long-term assets 1,249 1,303
Total assets 265,096 273,003
Current liabilities:    
Accounts payable 11,125 16,930
Accrued expenses 13,111 16,190
Current portion of operating lease liabilities 4,497 4,302
Other current liabilities 20 41
Total current liabilities 28,753 37,463
Operating lease liabilities 42,365 43,268
Total liabilities 71,118 80,731
COMMITMENTS AND CONTINGENCIES (Note 12)
Shareholders’ equity:    
Common stock, no par value; shares authorized — 75,000; shares issued and outstanding 47,507 and 47,253, respectively 602,104 593,245
Accumulated other comprehensive loss (636) (978)
Accumulated deficit (407,490) (399,995)
Total shareholders’ equity 193,978 192,272
Total liabilities and shareholders’ equity $ 265,096 $ 273,003
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 47 $ 47
Common stock, shares authorized (in shares) 75,000,000 75,000,000
Common stock, shares issued (in shares) 47,507,000 47,253,000
Ending balance (in shares) 47,507,000 47,253,000
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue, Product and Service [Extensible List] Product [Member]  
Product sales, net $ 41,017 $ 35,852
Other revenue 0 222
Total revenue $ 41,017 36,074
Cost, Product and Service [Extensible List] Product [Member]  
Cost of product sales $ 14,497 12,622
Gross profit 26,520 23,452
Research and development 5,212 4,860
Selling, general and administrative 29,485 25,865
Total operating expenses 34,697 30,725
Loss from operations (8,177) (7,273)
Other income (expense):    
Interest income 839 88
Interest expense (145) (18)
Other (expense) income (12) 112
Total other income 682 182
Net loss $ (7,495) $ (7,091)
Net loss per common share:    
Basic (in USD per share) $ (0.16) $ (0.15)
Diluted (in USD per share) $ (0.16) $ (0.15)
Weighted-average common shares outstanding:    
Basic (in shares) 47,387 46,985
Diluted (in shares) 47,387 46,985
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Statement of Comprehensive Income [Abstract]    
Net loss $ (7,495) $ (7,091)
Other comprehensive loss:    
Unrealized gain (loss) on investments 342 (459)
Comprehensive loss $ (7,153) $ (7,550)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   46,880    
Beginning balance at Dec. 31, 2021 $ 170,462 $ 553,902 $ (154) $ (383,286)
Increase (Decrease) in Shareholders' Equity        
Net loss (7,091)     (7,091)
Stock-based compensation expense 9,531 $ 9,531    
Stock option exercises (in shares)   125    
Stock option exercises 1,155 $ 1,155    
Shares issued under the Employee Stock Purchase Plan (in shares)   9    
Shares issued under the Employee Stock Purchase Plan 310 $ 310    
Issuance of stock for restricted stock unit vesting (in shares)   108    
Restricted stock withheld for employee tax remittance (in shares)   (41)    
Restricted stock withheld for employee tax remittance (1,423) $ (1,423)    
Unrealized gain (loss) on investment (459)   (459)  
Ending balance (in shares) at Mar. 31, 2022   47,081    
Ending balance at Mar. 31, 2022 $ 172,485 $ 563,475 (613) (390,377)
Beginning balance (in shares) at Dec. 31, 2022 47,253 47,253    
Beginning balance at Dec. 31, 2022 $ 192,272 $ 593,245 (978) (399,995)
Increase (Decrease) in Shareholders' Equity        
Net loss (7,495)     (7,495)
Stock-based compensation expense 8,731 $ 8,731    
Stock option exercises (in shares)   132    
Stock option exercises 2,009 $ 2,009    
Shares issued under the Employee Stock Purchase Plan (in shares)   11    
Shares issued under the Employee Stock Purchase Plan 216 $ 216    
Issuance of stock for restricted stock unit vesting (in shares)   183    
Restricted stock withheld for employee tax remittance (in shares)   (72)    
Restricted stock withheld for employee tax remittance (2,097) $ (2,097)    
Unrealized gain (loss) on investment $ 342   342  
Ending balance (in shares) at Mar. 31, 2023 47,507 47,507    
Ending balance at Mar. 31, 2023 $ 193,978 $ 602,104 $ (636) $ (407,490)
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating activities:    
Net loss $ (7,495) $ (7,091)
Adjustments to reconcile net loss to net cash flows from operating activities:    
Depreciation and amortization expense 1,158 873
Stock-based compensation expense 8,731 9,531
Amortization of premiums and discounts on marketable securities (290) 194
Amortization of debt issuance costs 54 0
Non-cash lease costs 1,112 1,076
Other 12 4
Changes in operating assets and liabilities:    
Inventory 616 (1,004)
Accounts receivable 8,180 5,582
Other current assets 263 (847)
Accounts payable (274) (219)
Accrued expenses (3,079) (3,734)
Operating lease liabilities (1,128) (897)
Net cash provided by operating activities 7,860 3,468
Investing activities:    
Purchases of investments (9,787) (12,629)
Sales and maturities of investments 21,500 5,041
Expenditures for property and equipment (1,413) (3,081)
Purchases of intangible assets (7,500) 0
Net cash provided by (used in) investing activities 2,800 (10,669)
Financing activities:    
Net proceeds from common stock issuance 2,225 1,465
Payments on employee’s behalf for taxes related to vesting of restricted stock unit awards (2,097) (943)
Other (21) (19)
Net cash provided by financing activities 107 503
Net increase (decrease) in cash, cash equivalents, and restricted cash 10,767 (6,698)
Cash, cash equivalents, and restricted cash at beginning of period 51,067 68,541
Cash, cash equivalents, and restricted cash at end of period 61,834 61,843
Supplemental disclosure of cash flow information:    
Right-of-use asset and lease liability recognized 419 0
Additions to property and equipment included in accounts payable 2,282 317
Restricted stock held for employee tax remittance included in accounts payable 0 480
Reconciliation of amounts within the condensed consolidated balance sheets:    
Cash and cash equivalents 61,834 55,659
Restricted cash 0 6,184
Total cash, cash equivalents, and restricted cash at end of period $ 61,834 $ 61,843
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Organization
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization Organization
Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI®, Epicel® and NexoBrid®.

MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) to commercialize NexoBrid (anacaulase-bcdb) in North America. On December 28, 2022, the U.S. Food and Drug Administration (“FDA”) approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. The Company operates its business primarily in the U.S. in one reportable segment - the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific diseases.

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

COVID-19

In March 2020, the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-19”) to be a pandemic, which contributed to an economic downturn on a global scale, as well as significant volatility in the financial markets. At the time of the pandemic’s inception, and at times throughout its duration, there was significant volatility in the Company’s results of operations on a quarterly basis due to the widespread and periodic cancellation or delay of elective MACI surgical procedures throughout the U.S., staffing shortages and the Company’s ability to access customers. Based on declining COVID-related statistics, the U.S. Department of Health and Human Services has announced that the federal Public Health Emergency for COVID-19 is set to expire at the end of the day on May 11, 2023. Although at this juncture the pandemic’s effects on the Company’s business and results of operations have moderated, should a resurgence of COVID-19 occur it could result in additional disruptions that could impact the Company’s business and operations in the future, including intermittent restrictions on the ability of Company personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact its capacity to manufacture, sell and support the use of its products.

The War in Ukraine

The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.
Liquidity

The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of March 31, 2023, the Company had an accumulated deficit of $407.5 million and had a net loss of $7.5 million during the three months ended March 31, 2023. The Company had cash and cash equivalents of $61.8 million and investments of $77.4 million as of March 31, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation (“FDIC”), the loss of which could have a negative effect on our operations and liquidity. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.

The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses.

The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 23, 2023 (“Annual Report”).

Recent Accounting Pronouncements

No new accounting standards were adopted during the three months ended March 31, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue
 3 Months Ended
Mar. 31, 2023
Risks and Uncertainties [Abstract]  
Revenue Revenue
Revenue Recognition and Product Sales, Net

The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and NexoBrid following the five-step model in Accounting Standards Codification 606, Revenue Recognition.

MACI Biopsy Kits

MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.

MACI Implants

The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc. (“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate.

Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration.

When the Company sells MACI the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with ASC 326, Financial Instruments - Credit Losses. The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of March 31, 2023. The total allowance for uncollectible consideration as of March 31, 2023 and December 31, 2022 was $7.1 million and $6.1 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the three months ended March 31, 2023.

Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year.
Epicel

The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital.

NexoBrid

The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020 the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA upon delivery, pursuant to this additional award.

Additionally, on December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.
Revenue by Product and Customer

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended March 31,
Revenue by product (in thousands) 20232022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)
$22,698 $15,190 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
3,485 3,369 
Implants sold direct based on contracted rates (c)
6,919 5,634 
Implants sold direct subject to third-party reimbursement (d)
501 861 
Biopsy kits - direct bill535 522 
Change in estimates related to prior periods (e)
52 419 
Total MACI implants and kits34,190 25,995 
Epicel
Direct bill (hospital)6,827 9,857 
NexoBrid revenue (f)
— 222 
Total revenue$41,017 $36,074 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components
 3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Selected Balance Sheet Components Selected Balance Sheet Components
Inventory

Inventory consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Raw materials$14,264 $15,101 
Work-in-process1,043 832 
Finished goods63 53 
Total inventory$15,370 $15,986 
Property and Equipment

Property and Equipment, net consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Machinery and equipment$5,212 $5,041 
Furniture, fixtures and office equipment1,710 1,710 
Computer equipment and software8,208 8,224 
Leasehold improvements14,120 13,689 
Construction in process8,121 5,438 
Financing right-of-use lease28 37 
Total property and equipment, gross37,399 34,139 
Less accumulated depreciation(19,202)(18,302)
Total property and equipment, net$18,197 $15,837 

Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.0 million and $0.9 million, respectively.
 
Intangible Assets

Intangible assets, net consisted of the following:

March 31, 2023December 31, 2022
(In thousands)Useful Live (in years)Amortization MethodCostAccumulated AmortizationNetCostAccumulated AmortizationNet
NexoBrid license12Straight-line$7,500 $(156)$7,344 $7,500 $— $7,500 

Amortization expense for the three months ended March 31, 2023 was $0.2 million.

Future amortization expense of intangible assets as of March 31, 2023 is estimated to be as follows:

(In thousands)Amount
Remainder of 2023$469 
2024625 
2025625 
2026625 
2027625 
Thereafter4,375 
Total$7,344 

Accrued Expenses

Accrued Expenses consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Bonus related compensation$3,588 $7,132 
Employee related accruals2,739 3,101 
Insurance reimbursement-related liabilities5,769 5,030 
Other accrued expenses1,015 927 
Total accrued expenses$13,111 $16,190 
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Leases
 3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Leases Leases
The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment.

With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000.

On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

The term of the Burlington Lease is currently expected to begin mid-year 2023 (the “Commencement Date”). The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million in total, following certain reductions to the tenant improvement allowance to account for the costs associated with changes to the landlord’s work on the Premises, as requested by the Company. The tenant improvement allowance will be used towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date.
In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three months ended March 31, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three months ended March 31, 2023 and 2022, the Company recognized $1.7 million of operating lease expense. For the three months ended March 31, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense.


Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationMarch 31, 2023December 31, 2022
Assets
OperatingRight-of-use assets$40,851 $41,535 
FinanceProperty and equipment, net28 37 
Total leased assets$40,879 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$4,497 $4,302 
FinanceOther current liabilities20 41 
Non-current
OperatingOperating lease liabilities$42,365 $43,268 
Total leased liabilities$46,882 $47,611 
Leases Leases
The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment.

With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000.

On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.

The term of the Burlington Lease is currently expected to begin mid-year 2023 (the “Commencement Date”). The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.

The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million in total, following certain reductions to the tenant improvement allowance to account for the costs associated with changes to the landlord’s work on the Premises, as requested by the Company. The tenant improvement allowance will be used towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.

The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date.
In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.

For the three months ended March 31, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. For the three months ended March 31, 2023 and 2022, the Company recognized $1.7 million of operating lease expense. For the three months ended March 31, 2023 and 2022, the Company recognized less than $0.1 million of financing lease expense.


Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationMarch 31, 2023December 31, 2022
Assets
OperatingRight-of-use assets$40,851 $41,535 
FinanceProperty and equipment, net28 37 
Total leased assets$40,879 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$4,497 $4,302 
FinanceOther current liabilities20 41 
Non-current
OperatingOperating lease liabilities$42,365 $43,268 
Total leased liabilities$46,882 $47,611 
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Revolving Credit Agreement
 3 Months Ended
Mar. 31, 2023
Debt Disclosure [Abstract]  
Revolving Credit Agreement Revolving Credit Agreement
On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement.

Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio.

The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit
Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of March 31, 2023, there are no outstanding borrowings under the Revolving Credit Agreement.

The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement).

The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.

Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (“Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.

Stock Compensation Expense

Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:
 Three Months Ended March 31,
(in thousands)20232022
Cost of product sales$885 $1,118 
Research and development977 1,350 
Selling, general and administrative6,869 7,063 
Total non-cash stock-based compensation expense$8,731 $9,531 

Service-Based Stock Options

During the three months ended March 31, 2023 and 2022, the Company granted service-based options to purchase common stock of 467,957 and 993,589, respectively. The weighted-average grant-date fair value of service-based options granted during the three months ended March 31, 2023 and 2022 was $18.00 and $20.99 per option, respectively.

Restricted Stock Units
During the three months ended March 31, 2023 and 2022, the Company granted 496,505 and 343,022 restricted stock units, respectively. The weighted-average grant-date fair value of restricted stock units granted during the three months ended March 31, 2023 and 2022 was $29.82 and $34.97 per unit, respectively.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Investments
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, Investments – Debt and Equity Securities, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:

March 31, 2023
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$14,306 $— $(48)$— $14,258 
Corporate notes43,157 — (559)— 42,598 
U.S. government securities4,920 5 — — 4,925 
U.S. government agency bonds15,600 — (29)— 15,571 
$77,983 $5 $(636)$— $77,352 
Classified as:
Short-term investments$57,442 
Long-term investments19,910 
$77,352 
December 31, 2022
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$15,707 $— $(101)$— $15,606 
Corporate notes52,159 — (831)— 51,328 
U.S. government agency bonds21,545 — (46)— 21,499 
$89,411 $— $(978)$— $88,433 
Classified as:
Short-term investments$68,471 
Long-term investments19,962 
$88,433 

As of March 31, 2023 and December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three months ended March 31, 2023 and 2022.
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The Company’s fair value measurements are classified and disclosed in one of the following three categories:

•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
•Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2022 to March 31, 2023.

The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:

 March 31, 2023December 31, 2022
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$39,906 $39,906 $— $— $1,262 $1,262 $— $— 
Commercial paper14,258 — 14,258 — 15,606 — 15,606 — 
Corporate notes42,598 — 42,598 — 51,328 — 51,328 — 
U.S. government securities4,925 — 4,925 — — — — — 
U.S. government agency bonds (a)
15,571 — 15,571 — 27,976 — 27,976 — 
$117,258 $39,906 $77,352 $— $96,172 $1,262 $94,910 $— 

(a) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.
The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost which approximates fair value.
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Common Share
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Net Loss Per Common Share Net Loss Per Common Share
A summary of net loss per common share is presented below:
 Three Months Ended March 31,
(Amounts in thousands, except per share amounts)20232022
Net loss$(7,495)$(7,091)
  
Basic weighted-average common shares outstanding47,387 46,985 
Effect of dilutive stock options and restricted stock units— — 
Diluted weighted-average common shares outstanding47,387 46,985 
Basic loss per common share$(0.16)$(0.15)
Diluted loss per common share$(0.16)$(0.15)
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options6,918 6,479 
Restricted stock units954 625 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
NexoBrid License and Supply Agreements
 3 Months Ended
Mar. 31, 2023
Related Party Transactions [Abstract]  
NexoBrid License and Supply Agreements NexoBrid License and Supply Agreements
On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological product, which was approved by the FDA on December 28, 2022 for commercial use in the U.S. NexoBrid contains proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.

Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.

In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. Pursuant to the terms of the license agreement, in February 2023, the Company tendered to MediWound a $7.5 million regulatory milestone payment following the FDA’s BLA approval of NexoBrid on December 28, 2022. The Company recorded the $7.5 million milestone payment for the licensing rights to commercially sell NexoBrid in the U.S., as an intangible asset (see Note 4, “Selected Balance Sheet Components” for further details).

The Company is additionally obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of March 31, 2023, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound will manufacture NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply.
Additionally, beginning in 2020 BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company has received a percentage of gross profit for sales directly to BARDA. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.

On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA, upon delivery, pursuant to this additional award.
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.

As of March 31, 2023, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events
 3 Months Ended
Mar. 31, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding into an escrow account maintained by the escrow agent a portion of its share of tenant improvement construction costs at the facility, which will be designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024. Additionally, and in order to support the expansion of the Company’s autologous cell manufacturing operations at the new facility in Burlington, the Company plans to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment.
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation (Policies)
 3 Months Ended
Mar. 31, 2023
Accounting Policies [Abstract]  
Concentration of Credit Risk
Concentration of Credit Risk

Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation (“FDIC”), the loss of which could have a negative effect on our operations and liquidity. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.
Recent Accounting Pronouncements
Recent Accounting Pronouncements

No new accounting standards were adopted during the three months ended March 31, 2023. The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue (Tables)
 3 Months Ended
Mar. 31, 2023
Risks and Uncertainties [Abstract]  
Schedule of disaggregation of revenue
The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:
 Three Months Ended March 31,
Revenue by product (in thousands) 20232022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)
$22,698 $15,190 
Implants subject to third party reimbursement sold through a specialty pharmacy (b)
3,485 3,369 
Implants sold direct based on contracted rates (c)
6,919 5,634 
Implants sold direct subject to third-party reimbursement (d)
501 861 
Biopsy kits - direct bill535 522 
Change in estimates related to prior periods (e)
52 419 
Total MACI implants and kits34,190 25,995 
Epicel
Direct bill (hospital)6,827 9,857 
NexoBrid revenue (f)
— 222 
Total revenue$41,017 $36,074 
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components (Tables)
 3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Schedule of inventory
Inventory consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Raw materials$14,264 $15,101 
Work-in-process1,043 832 
Finished goods63 53 
Total inventory$15,370 $15,986 
Schedule of property and equipment, net
Property and Equipment, net consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Machinery and equipment$5,212 $5,041 
Furniture, fixtures and office equipment1,710 1,710 
Computer equipment and software8,208 8,224 
Leasehold improvements14,120 13,689 
Construction in process8,121 5,438 
Financing right-of-use lease28 37 
Total property and equipment, gross37,399 34,139 
Less accumulated depreciation(19,202)(18,302)
Total property and equipment, net$18,197 $15,837 
Schedule of finite-lived intangible assets
Intangible assets, net consisted of the following:

March 31, 2023December 31, 2022
(In thousands)Useful Live (in years)Amortization MethodCostAccumulated AmortizationNetCostAccumulated AmortizationNet
NexoBrid license12Straight-line$7,500 $(156)$7,344 $7,500 $— $7,500 
Schedule of finite-lived intangible assets, future amortization expense
Future amortization expense of intangible assets as of March 31, 2023 is estimated to be as follows:

(In thousands)Amount
Remainder of 2023$469 
2024625 
2025625 
2026625 
2027625 
Thereafter4,375 
Total$7,344 
Schedule of accrued expenses
Accrued Expenses consisted of the following:

(In thousands)March 31, 2023December 31, 2022
Bonus related compensation$3,588 $7,132 
Employee related accruals2,739 3,101 
Insurance reimbursement-related liabilities5,769 5,030 
Other accrued expenses1,015 927 
Total accrued expenses$13,111 $16,190 
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Leases (Tables)
 3 Months Ended
Mar. 31, 2023
Leases [Abstract]  
Schedule of assets and liabilities
Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationMarch 31, 2023December 31, 2022
Assets
OperatingRight-of-use assets$40,851 $41,535 
FinanceProperty and equipment, net28 37 
Total leased assets$40,879 $41,572 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$4,497 $4,302 
FinanceOther current liabilities20 41 
Non-current
OperatingOperating lease liabilities$42,365 $43,268 
Total leased liabilities$46,882 $47,611 
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of non-cash stock-based compensation expense
Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:
 Three Months Ended March 31,
(in thousands)20232022
Cost of product sales$885 $1,118 
Research and development977 1,350 
Selling, general and administrative6,869 7,063 
Total non-cash stock-based compensation expense$8,731 $9,531 
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Investments (Tables)
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of fair value of securities, not including cash The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:
March 31, 2023
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$14,306 $— $(48)$— $14,258 
Corporate notes43,157 — (559)— 42,598 
U.S. government securities4,920 5 — — 4,925 
U.S. government agency bonds15,600 — (29)— 15,571 
$77,983 $5 $(636)$— $77,352 
Classified as:
Short-term investments$57,442 
Long-term investments19,910 
$77,352 
December 31, 2022
Gross UnrealizedEstimated Fair Value
(In thousands)Amortized CostGainsLossesCredit Losses
Commercial paper$15,707 $— $(101)$— $15,606 
Corporate notes52,159 — (831)— 51,328 
U.S. government agency bonds21,545 — (46)— 21,499 
$89,411 $— $(978)$— $88,433 
Classified as:
Short-term investments$68,471 
Long-term investments19,962 
$88,433 
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Schedule of valuation of the company's investments and financial instruments that are measured at fair value on a recurring basis
The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:

 March 31, 2023December 31, 2022
  Fair value measurement category Fair value measurement category
(In thousands)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3
Assets:
Money market funds$39,906 $39,906 $— $— $1,262 $1,262 $— $— 
Commercial paper14,258 — 14,258 — 15,606 — 15,606 — 
Corporate notes42,598 — 42,598 — 51,328 — 51,328 — 
U.S. government securities4,925 — 4,925 — — — — — 
U.S. government agency bonds (a)
15,571 — 15,571 — 27,976 — 27,976 — 
$117,258 $39,906 $77,352 $— $96,172 $1,262 $94,910 $— 

(a) Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Common Share (Tables)
 3 Months Ended
Mar. 31, 2023
Earnings Per Share [Abstract]  
Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method
A summary of net loss per common share is presented below:
 Three Months Ended March 31,
(Amounts in thousands, except per share amounts)20232022
Net loss$(7,495)$(7,091)
  
Basic weighted-average common shares outstanding47,387 46,985 
Effect of dilutive stock options and restricted stock units— — 
Diluted weighted-average common shares outstanding47,387 46,985 
Basic loss per common share$(0.16)$(0.15)
Diluted loss per common share$(0.16)$(0.15)
Anti-dilutive shares excluded from diluted net loss per common share:
Stock options6,918 6,479 
Restricted stock units954 625 
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Organization (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
segment
product
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Number of commercial-stage products | product 3    
Number of reportable segments | segment 1    
Accumulated deficit $ 407,490   $ 399,995
Net loss 7,495 $ 7,091  
Cash and cash equivalents 61,834 $ 55,659 $ 51,067
Short term investments $ 77,400    
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue - Narrative (Details)
$ in Millions
 3 Months Ended
May 09, 2023
USD ($)
Mar. 31, 2023
USD ($)
pharmacy
Dec. 31, 2022
USD ($)
Disaggregation of Revenue [Line Items]      
Number of specialty pharmacies | pharmacy   2  
Allowance for doubtful accounts   $ 7.1 $ 6.1
Change in estimate of uncollectible (percent)   0.50%  
Change in revenue recognized due to 0.5% change in uncollectible percentage   $ 0.3  
MediWound Ltd | Subsequent event      
Disaggregation of Revenue [Line Items]      
Additional funding $ 3.0    
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue - Summary of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Product sales, net $ 41,017 $ 35,852
NexoBrid revenue 0 222
Total revenue 41,017 36,074
Accounting Standards Update 2014-09 | Change in estimates related to prior periods    
Disaggregation of Revenue [Line Items]    
Product sales, net 52 419
M A C I Implants and kits    
Disaggregation of Revenue [Line Items]    
Product sales, net 34,190 25,995
Through Intermediary | MACI implants and kits | Contract rate    
Disaggregation of Revenue [Line Items]    
Product sales, net 22,698 15,190
Through Intermediary | MACI implants and kits | Time-and-materials contract    
Disaggregation of Revenue [Line Items]    
Product sales, net 3,485 3,369
Time-and-materials contract | MACI implants and kits | Time-and-materials contract    
Disaggregation of Revenue [Line Items]    
Product sales, net 501 861
Provider or Facility | MACI implants and kits | Contract rate    
Disaggregation of Revenue [Line Items]    
Product sales, net 6,919 5,634
Provider or Facility | NexoBrid    
Disaggregation of Revenue [Line Items]    
NexoBrid revenue 0 222
Directly to consumer | Biopsy kits    
Disaggregation of Revenue [Line Items]    
Product sales, net 535 522
Directly to consumer | Epicel    
Disaggregation of Revenue [Line Items]    
Product sales, net $ 6,827 $ 9,857
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components - Summary of inventory (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Inventory:    
Raw materials $ 14,264 $ 15,101
Work-in-process 1,043 832
Finished goods 63 53
Total inventory $ 15,370 $ 15,986
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components - Schedule of property and equipment, net (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Property and equipment, net:    
Financing right-of-use lease $ 28 $ 37
Total property and equipment, gross 37,399 34,139
Less accumulated depreciation (19,202) (18,302)
Total property and equipment, net 18,197 15,837
Machinery and equipment    
Property and equipment, net:    
Total property and equipment, gross 5,212 5,041
Furniture, fixtures and office equipment    
Property and equipment, net:    
Total property and equipment, gross 1,710 1,710
Computer equipment and software    
Property and equipment, net:    
Total property and equipment, gross 8,208 8,224
Leasehold improvements    
Property and equipment, net:    
Total property and equipment, gross 14,120 13,689
Construction in process    
Property and equipment, net:    
Total property and equipment, gross $ 8,121 $ 5,438
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Property, Plant and Equipment [Line Items]    
Depreciation $ 1.0 $ 0.9
Licensing Agreements    
Property, Plant and Equipment [Line Items]    
Amortization of intangible assets $ 0.2  
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Total $ 7,344 $ 7,500
Licensing Agreements    
Property, Plant and Equipment [Line Items]    
Useful Live (in years) 12 years 12 years
Cost $ 7,500 $ 7,500
Accumulated Amortization (156) 0
Total $ 7,344 $ 7,500
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Total $ 7,344 $ 7,500
Licensing Agreements    
Finite-Lived Intangible Assets [Line Items]    
Remainder of 2023 469  
2024 625  
2025 625  
2026 625  
2027 625  
Thereafter 4,375  
Total $ 7,344 $ 7,500
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.1
Selected Balance Sheet Components - Schedule of accrued expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Accrued expenses    
Bonus related compensation $ 3,588 $ 7,132
Employee related accruals 2,739 3,101
Insurance reimbursement-related liabilities 5,769 5,030
Other accrued expenses 1,015 927
Total accrued expenses $ 13,111 $ 16,190
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Narrative (Details)
ft² in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended
Jan. 28, 2022
USD ($)
ft²
$ / ft²
renewal_option
Jan. 31, 2022
USD ($)
Mar. 31, 2023
USD ($)
Mar. 31, 2022
USD ($)
Lessee, Lease, Description [Line Items]        
Short-term lease costs (less than)     $ 100 $ 100
Operating lease expense     1,700 1,700
Finance lease expense (less than)     100 $ 100
25 Network Drive, Burlington, Massachusetts        
Lessee, Lease, Description [Line Items]        
Area of real estate property | ft² 126      
Rent start date, term 13 months      
Term of contract 144 months      
Number of renewal options | renewal_option 1      
Lease option to extend term 10 years      
Annual lease per square foot | $ / ft² 57      
Annual lease base rent square subject to increase percentage 2.50%      
Tenant improvement allowance per square foot | $ / ft² 200      
Tenant improvement allowance $ 24,400      
Letter of credit cash deposit   $ 6,000    
Letter of credit cash deposit lease year three   4,200    
Letter of credit cash deposit lease year six   $ 1,800    
Minimum | 25 Network Drive, Burlington, Massachusetts        
Lessee, Lease, Description [Line Items]        
Monthly contractual lease payments 600      
Minimum | Ann Arbor Michigan        
Lessee, Lease, Description [Line Items]        
Monthly contractual lease payments     17  
Maximum | 25 Network Drive, Burlington, Massachusetts        
Lessee, Lease, Description [Line Items]        
Monthly contractual lease payments $ 800      
Maximum | Ann Arbor Michigan        
Lessee, Lease, Description [Line Items]        
Monthly contractual lease payments     $ 18  
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.1
Leases - Summary of assets and liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Assets    
Operating $ 40,851 $ 41,535
Finance 28 37
Total leased assets 40,879 41,572
Current    
Operating 4,497 4,302
Finance 20 41
Non-current    
Operating 42,365 43,268
Total leased liabilities $ 46,882 $ 47,611
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List] Property and equipment, net Property and equipment, net
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List] Other current liabilities Other current liabilities
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.1
Revolving Credit Agreement (Details) - Line of credit
Jul. 29, 2022
USD ($)
Mar. 31, 2023
USD ($)
Debt Instrument [Line Items]    
Issuance of letters of credit $ 6,200,000  
Revolving credit facility    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 150,000,000  
Debt instrument, term 5 years  
Debt issuance costs, net $ 1,100,000  
Outstanding borrowings   $ 0
Leverage ratio 3.50  
Increase option for leverage ratio 4.00  
Revolving credit facility | Minimum    
Debt Instrument [Line Items]    
Line of credit facility, commitment fee (in percent) 0.20%  
Revolving credit facility | Maximum    
Debt Instrument [Line Items]    
Line of credit facility, commitment fee (in percent) 0.25%  
Revolving credit facility | SOFR    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 0.10%  
Revolving credit facility | SOFR | Minimum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 1.25%  
Revolving credit facility | SOFR | Maximum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 2.50%  
Revolving credit facility | Base rate | Minimum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 0.25%  
Revolving credit facility | Base rate | Maximum    
Debt Instrument [Line Items]    
Basis spread on variable rate (in percent) 1.50%  
Letter of credit    
Debt Instrument [Line Items]    
Maximum borrowing capacity $ 15,000,000  
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Expense (Details) - Employee stock purchase plan and service-based stock options - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total non-cash stock-based compensation expense $ 8,731 $ 9,531
Cost of product sales    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total non-cash stock-based compensation expense 885 1,118
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total non-cash stock-based compensation expense 977 1,350
Selling, general and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total non-cash stock-based compensation expense $ 6,869 $ 7,063
XML 51 R42.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Narrative (Details) - $ / shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stock options    
Stock-Based Compensation    
Granted (in shares) 467,957 993,589
Weighted average grant-date fair value (in dollars per share) $ 18.00 $ 20.99
Restricted stock units    
Stock-Based Compensation    
Restricted stock units granted (shares) 496,505 343,022
Weighted-average grant date fair value (in dollars per share) $ 29.82 $ 34.97
XML 52 R43.htm IDEA: XBRL DOCUMENT v3.23.1
Investments (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Marketable Securities [Line Items]      
Amortized Cost $ 77,983,000   $ 89,411,000
Gains 5,000   0
Losses (636,000)   (978,000)
Credit Losses 0   0
Estimated Fair Value $ 77,352,000   $ 88,433,000
Remaining contractual maturity period 3 years   3 years
Impairments of assets $ 0 $ 0  
Short-term investments      
Marketable Securities [Line Items]      
Estimated Fair Value 57,442,000   $ 68,471,000
Long-term investments      
Marketable Securities [Line Items]      
Estimated Fair Value 19,910,000   19,962,000
Commercial paper      
Marketable Securities [Line Items]      
Amortized Cost 14,306,000   15,707,000
Gains 0   0
Losses (48,000)   (101,000)
Credit Losses 0   0
Estimated Fair Value 14,258,000   15,606,000
Corporate notes      
Marketable Securities [Line Items]      
Amortized Cost 43,157,000   52,159,000
Gains 0   0
Losses (559,000)   (831,000)
Credit Losses 0   0
Estimated Fair Value 42,598,000   51,328,000
U.S. government securities      
Marketable Securities [Line Items]      
Amortized Cost 4,920,000    
Gains 5,000    
Losses 0    
Credit Losses 0    
Estimated Fair Value 4,925,000    
U.S. government agency bonds      
Marketable Securities [Line Items]      
Amortized Cost 15,600,000   21,545,000
Gains 0   0
Losses (29,000)   (46,000)
Credit Losses 0   0
Estimated Fair Value $ 15,571,000   $ 21,499,000
XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Fair Value Measurements (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value $ 77,352 $ 88,433
U.S. government securities    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 4,925  
U.S. government agency bonds    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 15,571 21,499
Recurring    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 117,258 96,172
Recurring | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 39,906 1,262
Recurring | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 77,352 94,910
Recurring | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Assets, fair value 0 0
Recurring | Commercial paper    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 14,258 15,606
Recurring | Commercial paper | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Commercial paper | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 14,258 15,606
Recurring | Commercial paper | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Corporate notes    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 42,598 51,328
Recurring | Corporate notes | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Corporate notes | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 42,598 51,328
Recurring | Corporate notes | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government securities    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 4,925 0
Recurring | U.S. government securities | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government securities | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 4,925 0
Recurring | U.S. government securities | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government agency bonds    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 15,571 27,976
Recurring | U.S. government agency bonds | Cash and cash equivalents    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value   6,500
Recurring | U.S. government agency bonds | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | U.S. government agency bonds | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 15,571 27,976
Recurring | U.S. government agency bonds | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Debt securities, fair value 0 0
Recurring | Money market funds    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 39,906 1,262
Recurring | Money market funds | Level 1    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 39,906 1,262
Recurring | Money market funds | Level 2    
Liabilities that are measured at fair value on a recurring basis    
Money market funds 0 0
Recurring | Money market funds | Level 3    
Liabilities that are measured at fair value on a recurring basis    
Money market funds $ 0 $ 0
XML 54 R45.htm IDEA: XBRL DOCUMENT v3.23.1
Net Loss Per Common Share (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Net Income (Loss) Attributable to Parent [Abstract]    
Net loss $ (7,495) $ (7,091)
Basic weighted-average common shares outstanding (in shares) 47,387 46,985
Effect of dilutive stock options and restricted stock units (in shares) 0 0
Diluted weighted-average common shares outstanding (in shares) 47,387 46,985
Basic loss per common share (in USD per share) $ (0.16) $ (0.15)
Diluted loss per common share (in USD per share) $ (0.16) $ (0.15)
Stock options    
Anti-dilutive shares excluded from diluted net loss per common share:    
Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares) 6,918 6,479
Restricted stock units    
Anti-dilutive shares excluded from diluted net loss per common share:    
Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares) 954 625
XML 55 R46.htm IDEA: XBRL DOCUMENT v3.23.1
NexoBrid License and Supply Agreements (Details) - MediWound Ltd - USD ($)
$ in Millions
 1 Months Ended
May 09, 2023
May 31, 2019
Feb. 28, 2023
Related Party Transaction [Line Items]      
Consideration payment for license   $ 17.5  
Contingent consideration   7.5 $ 7.5
Maximum contingent consideration   125.0  
Sales threshold for first milestone   $ 75.0  
Term of supply agreement   5 years  
Renewal term of supply agreement   24 months  
Subsequent event      
Related Party Transaction [Line Items]      
Additional funding $ 3.0    
XML 56 R47.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Events (Details) - Subsequent event - 25 Network Drive, Burlington, Massachusetts
$ in Millions
Apr. 30, 2023
USD ($)
Subsequent Event [Line Items]  
Percent contributed to escrow account 50.00%
Escrow deposit amount $ 28.3
Remaining percent to be contributed to escrow account 50.00%
XML 57 vcel-20230331_htm.xml IDEA: XBRL DOCUMENT 0000887359 2023-01-01 2023-03-31 0000887359 2023-04-30 0000887359 2023-03-31 0000887359 2022-12-31 0000887359 2022-01-01 2022-03-31 0000887359 us-gaap:CommonStockMember 2022-12-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000887359 us-gaap:RetainedEarningsMember 2022-12-31 0000887359 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000887359 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000887359 us-gaap:CommonStockMember 2023-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000887359 us-gaap:RetainedEarningsMember 2023-03-31 0000887359 us-gaap:CommonStockMember 2021-12-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000887359 us-gaap:RetainedEarningsMember 2021-12-31 0000887359 2021-12-31 0000887359 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000887359 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000887359 us-gaap:CommonStockMember 2022-03-31 0000887359 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000887359 us-gaap:RetainedEarningsMember 2022-03-31 0000887359 2022-03-31 0000887359 vcel:MediWoundLtdMember us-gaap:SubsequentEventMember 2023-05-09 2023-05-09 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2023-01-01 2023-03-31 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember us-gaap:SalesChannelThroughIntermediaryMember 2022-01-01 2022-03-31 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2023-01-01 2023-03-31 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:SalesChannelThroughIntermediaryMember 2022-01-01 2022-03-31 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2023-01-01 2023-03-31 0000887359 vcel:ImplantsMember us-gaap:FixedPriceContractMember vcel:ProviderorFacilityMember 2022-01-01 2022-03-31 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2023-01-01 2023-03-31 0000887359 vcel:ImplantsMember us-gaap:TimeAndMaterialsContractMember us-gaap:TimeAndMaterialsContractMember 2022-01-01 2022-03-31 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-03-31 0000887359 vcel:BiopsyKitsMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-01-01 2022-03-31 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2023-01-01 2023-03-31 0000887359 us-gaap:AccountingStandardsUpdate201409Member us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember 2022-01-01 2022-03-31 0000887359 vcel:MACIImplantsAndKitsMember 2023-01-01 2023-03-31 0000887359 vcel:MACIImplantsAndKitsMember 2022-01-01 2022-03-31 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2023-01-01 2023-03-31 0000887359 vcel:EpicelMember us-gaap:SalesChannelDirectlyToConsumerMember 2022-01-01 2022-03-31 0000887359 vcel:NexoBridMember vcel:ProviderorFacilityMember 2023-01-01 2023-03-31 0000887359 vcel:NexoBridMember vcel:ProviderorFacilityMember 2022-01-01 2022-03-31 0000887359 us-gaap:MachineryAndEquipmentMember 2023-03-31 0000887359 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000887359 us-gaap:FurnitureAndFixturesMember 2023-03-31 0000887359 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000887359 vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember 2023-03-31 0000887359 vcel:ComputerEquipmentAndComputerSoftwareIntangibleAssetMember 2022-12-31 0000887359 us-gaap:LeaseholdImprovementsMember 2023-03-31 0000887359 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000887359 us-gaap:ConstructionInProgressMember 2023-03-31 0000887359 us-gaap:ConstructionInProgressMember 2022-12-31 0000887359 us-gaap:LicensingAgreementsMember 2023-01-01 2023-03-31 0000887359 us-gaap:LicensingAgreementsMember 2022-01-01 2022-12-31 0000887359 us-gaap:LicensingAgreementsMember 2023-03-31 0000887359 us-gaap:LicensingAgreementsMember 2022-12-31 0000887359 srt:MinimumMember vcel:AnnArborMichiganMember 2023-01-01 2023-03-31 0000887359 srt:MaximumMember vcel:AnnArborMichiganMember 2023-01-01 2023-03-31 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-01-28 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-01-28 2022-01-28 0000887359 srt:MinimumMember vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-01-28 2022-01-28 0000887359 srt:MaximumMember vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-01-28 2022-01-28 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember 2022-01-01 2022-01-31 0000887359 us-gaap:CommercialPaperMember 2023-03-31 0000887359 us-gaap:CorporateDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:USGovernmentDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:ShortTermInvestmentsMember 2023-03-31 0000887359 vcel:LongtermInvestmentsMember 2023-03-31 0000887359 us-gaap:CommercialPaperMember 2022-12-31 0000887359 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:ShortTermInvestmentsMember 2022-12-31 0000887359 vcel:LongtermInvestmentsMember 2022-12-31 0000887359 2022-01-01 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-03-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateNoteSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-03-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0000887359 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000887359 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-12-31 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 2022-07-29 0000887359 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2022-07-29 0000887359 us-gaap:LineOfCreditMember 2022-07-29 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-07-29 2022-07-29 0000887359 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-07-29 2022-07-29 0000887359 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-07-29 2022-07-29 0000887359 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-07-29 2022-07-29 0000887359 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-07-29 2022-07-29 0000887359 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 2022-07-29 0000887359 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2022-07-29 2022-07-29 0000887359 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2023-01-01 2023-03-31 0000887359 vcel:EmployeeStockAndEmployeeStockOptionMember 2022-01-01 2022-03-31 0000887359 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000887359 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000887359 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000887359 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000887359 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-03-31 0000887359 vcel:MediWoundLtdMember 2019-05-31 0000887359 vcel:MediWoundLtdMember 2023-02-28 0000887359 vcel:MediWoundLtdMember 2019-05-01 2019-05-31 0000887359 vcel:A25NetworkDriveBurlingtonMassachusettsMember us-gaap:SubsequentEventMember 2023-04-30 shares iso4217:USD iso4217:USD shares vcel:product vcel:segment vcel:pharmacy pure utr:sqft vcel:renewal_option iso4217:USD utr:sqft 0000887359 --12-31 2023 Q1 false http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#ProductMember http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2022#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent 10-Q true 2023-03-31 false 001-35280 VERICEL CORPORATION MI 94-3096597 64 Sidney Street Cambridge MA 02139 617 588-5555 Common Stock (No par value) VCEL NASDAQ Yes Yes Large Accelerated Filer false false false 47564919 61834000 51067000 57442000 68471000 47000 47000 38359000 46539000 15370000 15986000 4540000 4803000 177545000 186866000 18197000 15837000 7344000 7500000 40851000 41535000 19910000 19962000 1249000 1303000 265096000 273003000 11125000 16930000 13111000 16190000 4497000 4302000 20000 41000 28753000 37463000 42365000 43268000 71118000 80731000 75000000 75000000 47507000 47507000 47253000 47253000 602104000 593245000 -636000 -978000 -407490000 -399995000 193978000 192272000 265096000 273003000 41017000 35852000 0 222000 41017000 36074000 14497000 12622000 26520000 23452000 5212000 4860000 29485000 25865000 34697000 30725000 -8177000 -7273000 839000 88000 145000 18000 -12000 112000 682000 182000 -7495000 -7091000 -0.16 -0.16 -0.15 -0.15 47387000 47387000 46985000 46985000 -7495000 -7091000 342000 -459000 -7153000 -7550000 47253000 593245000 -978000 -399995000 192272000 -7495000 -7495000 8731000 8731000 132000 2009000 2009000 11000 216000 216000 183000 72000 2097000 2097000 342000 342000 47507000 602104000 -636000 -407490000 193978000 46880000 553902000 -154000 -383286000 170462000 -7091000 -7091000 9531000 9531000 125000 1155000 1155000 9000 310000 310000 108000 41000 1423000 1423000 -459000 -459000 47081000 563475000 -613000 -390377000 172485000 -7495000 -7091000 1158000 873000 8731000 9531000 290000 -194000 54000 0 1112000 1076000 -12000 -4000 -616000 1004000 -8180000 -5582000 -263000 847000 -274000 -219000 -3079000 -3734000 -1128000 -897000 7860000 3468000 9787000 12629000 21500000 5041000 1413000 3081000 7500000 0 2800000 -10669000 2225000 1465000 2097000 943000 -21000 -19000 107000 503000 10767000 -6698000 51067000 68541000 61834000 61843000 419000 0 2282000 317000 0 480000 61834000 55659000 0 6184000 61834000 61843000 Organization<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, or Vericel), was incorporated in March 1989 and began employee-based operations in 1991. The Company is a fully-integrated, commercial-stage biopharmaceutical company and is a leader in advanced therapies for the sports medicine and severe burn care markets. Vericel currently markets three commercial-stage products in the U.S., MACI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Epicel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and NexoBrid</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (“TBSA”). The Company also holds an exclusive license from MediWound Ltd. (“MediWound”) to commercialize NexoBrid (anacaulase-bcdb) in North America. On December 28, 2022, the U.S. Food and Drug Administration (“FDA”) approved a Biologics License Application (“BLA”) for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns. The Company operates its business primarily in the U.S. in one reportable segment - the research, product development, manufacture and distribution of cellular therapies and specialty biologics for use in the treatment of specific diseases.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="padding-right:72pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the spread of a novel strain of coronavirus (“COVID-19”) to be a pandemic, which contributed to an economic downturn on a global scale, as well as significant volatility in the financial markets. At the time of the pandemic’s inception, and at times throughout its duration, there was significant volatility in the Company’s results of operations on a quarterly basis due to the widespread and periodic cancellation or delay of elective MACI surgical procedures throughout the U.S., staffing shortages and the Company’s ability to access customers. Based on declining COVID-related statistics, the U.S. Department of Health and Human Services has announced that the federal Public Health Emergency for COVID-19 is set to expire at the end of the day on May 11, 2023. Although at this juncture the pandemic’s effects on the Company’s business and results of operations have moderated, should a resurgence of COVID-19 occur it could result in additional disruptions that could impact the Company’s business and operations in the future, including intermittent restrictions on the ability of Company personnel to travel and access customers for selling, marketing, training, case support and product development feedback, delays in approvals by regulatory bodies, delays in product development efforts, and additional government requirements or other incremental mitigation efforts that may further impact its capacity to manufacture, sell and support the use of its products.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">The War in Ukraine</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing war between Russia and Ukraine and the related sanctions and other penalties imposed by countries across the globe against Russia are continuing to create substantial uncertainty in the global economy and have contributed to heightened inflation and supply chain disruptions. While the Company does not have operations in Russia or Ukraine and does not have exposure to distributors, or third-party service providers in Russia or Ukraine, it is unable to predict the ultimate impact that these actions will have on the global economy or on its financial condition, results of operations, and cash flows as of the date of these condensed consolidated financial statements.</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023, the Company had an accumulated deficit of </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$407.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and had a </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net loss of $7.5 million during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> March 31, 2023. The Company had cash and cash equivalents of $61.8 million and investments of $77.4 million as of March 31, 2023. The Company expects that cash from the sales of its products and existing cash, cash equivalents, investments, and available borrowing capacity will be sufficient to support the Company’s current operations through at least 12 months from the issuance of these condensed consolidated financial statements. If revenues decline for a sustained period, the Company may need to access additional capital; however, the Company may not be able to obtain additional financing on acceptable terms or at all. The terms of any additional financing may adversely affect the holdings or the rights of the Company’s shareholders.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation (“FDIC”), the loss of which could have a negative effect on our operations and liquidity. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></div> 3 1 -407500000 -7500000 61800000 77400000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents and investments in marketable debt securities. The Company may maintain deposits in financial institutions in excess of the insurance coverage offered by the Federal Deposit Insurance Corporation (“FDIC”), the loss of which could have a negative effect on our operations and liquidity. The Company is closely monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions or other companies in the financial services industry or the financial services industry generally. The Company believes that it is not exposed to significant credit risk as its deposits, including cash and cash equivalents, are held at multiple high credit quality financial institutions. The Company has not experienced any losses on these deposits; however no assurances can be provided that there will not be losses experienced in the future. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated based on the fact that many of these securities are either government-backed or of high credit rating.</span></div> Basis of Presentation<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements of Vericel are unaudited and have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The preparation of condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expenses. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated balance sheet as of December 31, 2022 has been derived from the audited consolidated financial statements at that date, but does not include all the information and notes required by U.S. GAAP for complete financial statements. These c</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ondensed consolidated financial statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> should be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 23, 2023 (“Annual Report”).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new accounting standards were adopted during the three months ended March 31, 2023. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.</span></div> <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No new accounting standards were adopted during the three months ended March 31, 2023. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of any recent Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). Based on the assessment, the ASUs were determined to be either not applicable or are expected to have minimal impact on the Company’s condensed consolidated financial statements.</span></div> Revenue<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Product Sales, Net </span></div><div style="text-indent:-4.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes product revenue from sales of MACI biopsy kits, MACI implants, Epicel grafts and NexoBrid following the five-step model in Accounting Standards Codification 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition.</span></div><div style="text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MACI Biopsy Kits</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MACI biopsy kits are sold directly to hospitals and ambulatory surgical centers based on contracted rates in an approved contract or sales order. The Company recognizes MACI kit revenue upon delivery of the biopsy kit, at which time the customer (the facility) is in control of the kit. The kit is used by the doctor to provide a sample of cartilage tissue to the Company, which can later be used to manufacture a MACI implant. The ordering of the kit does not obligate the Company to manufacture an implant nor does the receipt of the cartilage tissue by the Company from the customer following biopsy. The customer’s order of an implant is separate from the process of ordering the biopsy kit. Therefore, the sale of the biopsy kit and any subsequent sale of an implant are distinct contracts and are accounted for separately.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MACI Implants</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company contracts with two specialty pharmacies, Orsini Pharmaceutical Services, Inc. (“Orsini”) and AllCare Plus Pharmacy, Inc. (“AllCare”) to distribute MACI in a manner in which the Company retains the credit and collection risk from the end customer. The Company pays both specialty pharmacies a fee for each patient to whom MACI is dispensed. Both Orsini and AllCare perform collection activities to collect payment from customers. The Company engages a third party to provide services in connection with a patient support program to manage patient cases and to ensure complete and correct billing information is provided to the insurers and hospitals. In addition, the Company also sells MACI directly to DMS Pharmaceutical Group, Inc. (“DMS”) for patients treated at military treatment facilities. The sales directly to DMS are made at a contracted rate.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior authorization and confirmation of coverage level by the patient’s private insurance plan, hospital or government payer is a prerequisite to the shipment of product to a patient. The Company recognizes product revenue from sales of all MACI implants upon delivery at which time the customer obtains control of the implant and the claim is billable. The total consideration that the Company expects to collect in exchange for MACI implants (the “Transaction Price”) may be fixed or variable. Direct sales to hospitals or distributors are recorded at a contracted price, and there are typically no forms of variable consideration. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company sells MACI the patient is responsible for payment; however, the Company is typically reimbursed by a third-party insurer or government payer, subject to a patient co-pay amount. Reimbursements from third-party insurers and government payers vary by patient and payer and are based on either contracted rates, publicly available rates, fee schedules or past payer precedents. Net product revenue is recognized net of estimated contractual allowances, which considers historical collection experience from both the payer and patient, denial rates and the terms of the Company’s contractual arrangements. The Company estimates expected collections for these transactions using the portfolio approach. The Company records a reduction to revenue at the time of sale for its estimate of the amount of consideration that will not be collected. In addition, potential credit risk exposure has been evaluated for the Company’s accounts receivable in accordance with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC 326, Financial Instruments - Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company assesses risk and determines a loss percentage by pooling accounts receivable based on similar risk characteristics. The loss percentage is calculated through the use of forecasts that are based on current and historical economic and financial information. This loss percentage was applied to the accounts receivables as of March 31, 2023. The total allowance for uncollectible consideration as of March 31, 2023 and December 31, 2022 was $7.1 million and $6.1 million, respectively. Changes to the estimate of the amount of consideration that will not be collected could have a material impact on the revenue recognized. A 50 basis points change to the estimated uncollectible percentage could result in an approximately $0.3 million decrease or increase in the revenue recognized for the three months ended March 31, 2023.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimates of the Transaction Price are recorded through revenue in the period in which such change occurs. Changes in estimates related to prior periods are shown in the Revenue by Product and Customer table below and relate primarily to changes in the initial expected reimbursement or collection expectation upon completion of the billing claims process for MACI implants that occurred in a prior year. </span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Epicel</span></div><div style="text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells Epicel directly to hospitals and burn centers based on contracted rates stated in an approved contract or purchase order. Similar to MACI, there is no obligation to manufacture Epicel grafts upon receipt of a skin biopsy, and Vericel has no contractual right to receive payment until the product is delivered to the hospital. The Company recognizes product revenue from sales of Epicel upon delivery to the hospital, at which time the customer is in control of the Epicel grafts and the claim is billable to the hospital. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NexoBrid</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into exclusive license and supply agreements with MediWound in May 2019, pursuant to which MediWound will manufacture and supply NexoBrid on a unit price basis, which may be increased pursuant to the terms of the agreements. Additionally, beginning in 2020 the U.S. Biomedical Advanced Research and Development Authority (“BARDA”) procured quantities of NexoBrid from MediWound, for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. The Company recognized revenue based on a percentage of gross profits for sales of NexoBrid to BARDA upon delivery, at which time BARDA was in control of the product. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA upon delivery, pursuant to this additional award.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, on December 28, 2022, the FDA approved a BLA for NexoBrid, granting a license for commercial use in the U.S. NexoBrid is a topically-administered biological product containing proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Product and Customer</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.775%"><tr><td style="width:1.0%"/><td style="width:70.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.194%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue by product (in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">MACI implants and kits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants based on contracted rate sold through a specialty pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants subject to third party reimbursement sold through a specialty pharmacy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct based on contracted rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct subject to third-party reimbursement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopsy kits - direct bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimates related to prior periods </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total MACI implants and kits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,995 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Epicel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct bill (hospital)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NexoBrid revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (f)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts. </span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).</span></div></td></tr></table></div> 2 7100000 6100000 0.0050 300000 3000000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:</span></div><div style="margin-bottom:9pt;margin-top:14pt;text-align:justify;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.775%"><tr><td style="width:1.0%"/><td style="width:70.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.193%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.194%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue by product (in thousands) </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">MACI implants and kits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants based on contracted rate sold through a specialty pharmacy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,698 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants subject to third party reimbursement sold through a specialty pharmacy </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,485 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,369 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct based on contracted rates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (c)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,634 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Implants sold direct subject to third-party reimbursement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biopsy kits - direct bill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimates related to prior periods </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total MACI implants and kits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,190 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,995 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Epicel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Direct bill (hospital)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,827 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,857 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">NexoBrid revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (f)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,017 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,074 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts. </span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(f) Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound (see Note 11).</span></div></td></tr></table></div> 22698000 15190000 3485000 3369000 6919000 5634000 501000 861000 535000 522000 52000 419000 34190000 25995000 6827000 9857000 0 222000 41017000 36074000 Selected Balance Sheet Components<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inventory</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,370 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,986 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property and Equipment</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing right-of-use lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,197 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.0 million and $0.9 million, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.103%"><tr><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.805%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Live (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NexoBrid license</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for the three months ended March 31, 2023 was $0.2 million.</span></div><div><span><br/></span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of March 31, 2023 is estimated to be as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Expenses</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.247%"><tr><td style="width:1.0%"/><td style="width:68.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus related compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reimbursement-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,111 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,264 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,370 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,986 </span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14264000 15101000 1043000 832000 63000 53000 15370000 15986000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and Equipment, net consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.813%"><tr><td style="width:1.0%"/><td style="width:68.446%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.396%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,041 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture, fixtures and office equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,710 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,224 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,689 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,121 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,438 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing right-of-use lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,399 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,302)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,197 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,837 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5212000 5041000 1710000 1710000 8208000 8224000 14120000 13689000 8121000 5438000 28000 37000 37399000 34139000 19202000 18302000 18197000 15837000 1000000 900000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net consisted of the following: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.103%"><tr><td style="width:1.0%"/><td style="width:14.228%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.805%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.967%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.264%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Live (in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Method</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NexoBrid license</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> P12Y P12Y 7500000 156000 7344000 7500000 0 7500000 200000 <div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense of intangible assets as of March 31, 2023 is estimated to be as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:75.946%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,344 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 469000 625000 625000 625000 625000 4375000 7344000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued Expenses consisted of the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.247%"><tr><td style="width:1.0%"/><td style="width:68.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.039%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.335%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bonus related compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,132 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance reimbursement-related liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,030 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,111 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,190 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 3588000 7132000 2739000 3101000 5769000 5030000 1015000 927000 13111000 16190000 Leases<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Burlington Lease is currently expected to begin mid-year 2023 (the “Commencement Date”). The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million in total, following certain reductions to the tenant improvement allowance to account for the costs associated with changes to the landlord’s work on the Premises, as requested by the Company. The tenant improvement allowance will be used towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date.</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023 and </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the Company recognized $1.7 million of operating lease expense. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023 and </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the Company recognized less than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of financing lease expense.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfMy0yLTEtMS02NDYyNw_9b81feb1-662e-4243-a7aa-39c9aa8ed75a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfMy0yLTEtMS02NDYyNw_fc7bda11-0b33-4867-9b5b-cadcf4f5d7f5">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfOC0yLTEtMS02NDYyNw_3f708039-162a-46b3-9539-fb188d7ed4d7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfOC0yLTEtMS02NDYyNw_cad42cf7-592f-4667-93ee-452dfe516a0a">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,882 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,611 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> Leases<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities in Ann Arbor, Michigan and Cambridge, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facilities include clean rooms, laboratories for MACI and Epicel manufacturing, and office space. The Company also leases offsite warehouse space, and other computer-related equipment. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the Ann Arbor facility, in March 2023, the Company entered into an amendment to that lease extending its term until April 30, 2025. Monthly contractual payments are expected to range from $17,000 to $18,000. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 28, 2022, the Company entered into a lease agreement (the “Burlington Lease”) to lease approximately 126,000 square feet of to-be-constructed manufacturing, laboratory and office space in Burlington, Massachusetts (the “Premises”). Once constructed, the Premises will serve as the Company’s new corporate headquarters and primary manufacturing facility.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of the Burlington Lease is currently expected to begin mid-year 2023 (the “Commencement Date”). The Company’s obligation to pay rent for the Premises will begin on the earlier of: 13 months from the Commencement Date; or the date on which the Company first occupies the Premises to conduct operations (the “Rent Commencement Date”). The initial term of the Lease is 144 months following the Rent Commencement Date. The Company has a one-time option to extend the term of the Lease for an additional 10 years, exercisable under certain conditions and at a market rate determined in accordance with the Burlington Lease.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual base rent of the Burlington Lease is initially $57 per square foot per year, subject to annual increases of 2.5%. Monthly contractual payments are expected to range from $0.6 million to $0.8 million. Additionally, the Company is responsible for reimbursing the landlord for the Company’s share of the Premises’ property taxes and certain other operating expenses. The Burlington Lease also provides for a tenant improvement allowance from the landlord in an amount equal to $200 per square foot of the Premises, or approximately $24.4 million in total, following certain reductions to the tenant improvement allowance to account for the costs associated with changes to the landlord’s work on the Premises, as requested by the Company. The tenant improvement allowance will be used towards the design and construction of certain tenant improvements made to the Premises, subject to the terms set forth in the Burlington Lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not involved in the initial construction of the core and shell of the building and will record the lease liability and right-of-use asset on its condensed consolidated balance sheet when the construction is substantially completed and it obtains control of the Premises, which is currently expected to be on or around the Commencement Date.</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, in connection with the execution of the Burlington Lease, the Company issued a letter of credit collateralized by cash deposits of approximately $6.0 million. Subsequent to the execution of the Revolving Credit Agreement on July 29, 2022 (see Note 8, “Revolving Credit Agreement” for further details), the letter of credit is issued under the sub-facility limit of the Revolving Credit Agreement. Such letter of credit shall be reduced to approximately $4.2 million and $1.8 million at the conclusion of the third and sixth lease years, respectively, provided certain conditions set forth in the Burlington Lease are satisfied.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, lease expense of less than $0.1 million was recorded related to short-term leases. </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023 and </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the Company recognized $1.7 million of operating lease expense. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 31, 2023 and </span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, the Company recognized less than </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="color:#222222;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of financing lease expense.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfMy0yLTEtMS02NDYyNw_9b81feb1-662e-4243-a7aa-39c9aa8ed75a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfMy0yLTEtMS02NDYyNw_fc7bda11-0b33-4867-9b5b-cadcf4f5d7f5">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfOC0yLTEtMS02NDYyNw_3f708039-162a-46b3-9539-fb188d7ed4d7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfOC0yLTEtMS02NDYyNw_cad42cf7-592f-4667-93ee-452dfe516a0a">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,882 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,611 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 17000 18000 126000 P13M P144M 1 P10Y 57 0.025 600000 800000 200 24400000 6000000 4200000 1800000 100000 100000 1700000 1700000 100000 100000 <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities are as follows:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.232%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,851 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfMy0yLTEtMS02NDYyNw_9b81feb1-662e-4243-a7aa-39c9aa8ed75a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfMy0yLTEtMS02NDYyNw_fc7bda11-0b33-4867-9b5b-cadcf4f5d7f5">Property and equipment, net</span></span></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,879 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,497 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfOC0yLTEtMS02NDYyNw_3f708039-162a-46b3-9539-fb188d7ed4d7"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmZjYjJkMzM0YjA3ZjRlM2FiYzdkY2Y5MDRlOGEwYzM1L3NlYzpmY2IyZDMzNGIwN2Y0ZTNhYmM3ZGNmOTA0ZThhMGMzNV80Ni9mcmFnOmEwMGQyN2E2ZDJlMTQyYWViOTJlODZhYmQxZTcyNzJlL3RhYmxlOjA1ODk1OGZiZjlmYzQxOWY5OTgyNmY5Mzg3NDc2MTNiL3RhYmxlcmFuZ2U6MDU4OTU4ZmJmOWZjNDE5Zjk5ODI2ZjkzODc0NzYxM2JfOC0yLTEtMS02NDYyNw_cad42cf7-592f-4667-93ee-452dfe516a0a">Other current liabilities</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,268 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total leased liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,882 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,611 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 40851000 41535000 28000 37000 40879000 41572000 4497000 4302000 20000 41000 42365000 43268000 46882000 47611000 Investments<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable debt securities held by the Company are classified as available-for-sale pursuant to ASC 320, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments – Debt and Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and carried at fair value in the accompanying condensed consolidated balance sheets on a settlement date basis. The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:right;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.668%"><tr><td style="width:1.0%"/><td style="width:27.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,983 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:right;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"/><td style="width:27.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,411 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(978)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023 and December 31, 2022, all marketable securities held by the Company had remaining contractual maturities of three years or less. There have been no impairments of the Company’s assets measured and carried at fair value during the three months ended March 31, 2023 and 2022.</span></div> The following tables summarize the gross unrealized gains and losses of the Company’s marketable securities:<div style="text-align:right;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.668%"><tr><td style="width:1.0%"/><td style="width:27.199%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,920 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,983 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(636)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,352 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,910 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:right;text-indent:13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"/><td style="width:27.366%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.681%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.141%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Credit Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(831)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,545 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,499 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,411 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(978)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Classified as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,471 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,962 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="9" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,433 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14306000 0 48000 0 14258000 43157000 0 559000 0 42598000 4920000 5000 0 0 4925000 15600000 0 29000 0 15571000 77983000 5000 636000 0 77352000 57442000 19910000 77352000 15707000 0 101000 0 15606000 52159000 0 831000 0 51328000 21545000 0 46000 0 21499000 89411000 0 978000 0 88433000 68471000 19962000 88433000 P3Y P3Y 0 0 Fair Value Measurements<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s fair value measurements are classified and disclosed in one of the following three categories:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The commercial paper, corporate notes, U.S. government securities, and U.S. government agency bonds are classified as Level 2 as they were valued based upon quoted market prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. There were no transfers into or out of Level 3 from December 31, 2022 to March 31, 2023. </span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.681%"><tr><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,258 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,906 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,172 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,910 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.</span></div>The fair values of the cash equivalents and marketable securities are based on observable market prices. The Company’s accounts receivables, accounts payable and accrued expenses are valued at cost which approximates fair value. <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the valuation of the Company’s financial instruments that are measured at fair value on a recurring basis:</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.681%"><tr><td style="width:1.0%"/><td style="width:27.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.184%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value measurement category</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,906 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,606 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,925 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agency bonds </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,571 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,976 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,258 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,906 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,352 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,172 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,910 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(a) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Approximately $6.5 million of U.S. government agency bonds had an original maturity of 90 days or less and were recorded as a cash equivalent as of December 31, 2022.</span></div> 39906000 39906000 0 0 1262000 1262000 0 0 14258000 0 14258000 0 15606000 0 15606000 0 42598000 0 42598000 0 51328000 0 51328000 0 4925000 0 4925000 0 0 0 0 0 15571000 0 15571000 0 27976000 0 27976000 0 117258000 39906000 77352000 0 96172000 1262000 94910000 0 6500000 Revolving Credit Agreement<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, the Company, as borrower, entered into a $150.0 million five-year senior secured revolving credit agreement by and among the Company, the other loan parties thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent (the “Revolving Credit Agreement”). The Revolving Credit Agreement includes a $15.0 million sub-facility for the issuance of letters of credit, of which the Company is utilizing approximately $6.2 million. Amounts available under the Revolving Credit Agreement are for the working capital needs and other general corporate purposes of the Company. The Company incurred and capitalized approximately $1.1 million of debt issuance costs related to the Revolving Credit Agreement.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding borrowings under the Revolving Credit Agreement bear interest, with pricing based from time to time at the Company’s election at (i) the Secured Overnight Financing Rate (“SOFR”) plus 0.10% plus a spread ranging from 1.25% to 2.50% as determined by the Company’s Total Net Leverage Ratio (as defined in the Revolving Credit Agreement) or (ii) the alternative base rate (as defined in the Revolving Credit Agreement) plus a spread ranging from 0.25% to 1.50% as determined by the Company’s Total Net Leverage Ratio. The Revolving Credit Agreement also includes a commitment fee, which ranges from 0.20% to 0.25% as determined by the Company’s Total Net Leverage Ratio.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is permitted to voluntarily prepay borrowings under the Revolving Credit Agreement, in whole or in part, without premium or penalty. On any business day on which the total amount of outstanding Revolving Loans (as defined in the Revolving Credit Agreement) and letters of credit exceeds the total Revolving Commitments (as defined in the Revolving Credit </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement), the Company must prepay the Revolving Loans in an amount equal to such excess. As of March 31, 2023, there are no outstanding borrowings under the Revolving Credit Agreement.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement contains a number of affirmative, negative, reporting and financial covenants, in each case subject to certain exceptions and materiality thresholds. The Revolving Credit Agreement requires the Company to be in quarterly compliance, measured on a trailing four quarter basis, with a financial covenant. The maximum Total Net Leverage Ratio (as defined in the Revolving Credit Agreement is 3.50 to 1.00. The Company may elect to increase the maximum Total Net Leverage Ratio to 4.00 to 1.00 for a period of four consecutive quarters in connection with a Permitted Acquisition (as defined in the Revolving Credit Agreement).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement contains usual and customary restrictions on the ability of the Company and its subsidiaries to: (i) incur additional indebtedness (ii) create liens; (iii) consolidate, merge, sell or otherwise dispose of all, or substantially all, of its assets; (iv) sell certain assets; (v) pay dividends on, repurchase or make distributions in respect of capital stock or make other restricted payments; (vi) make certain investments; (vii) repay subordinated indebtedness prior to stated maturity; and (viii) enter into certain transactions with its affiliates.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under the Revolving Credit Agreement are secured by first priority liens over substantially all of the assets of Vericel Corporation, excluding certain subsidiaries (subject to customary exclusions set forth in the Revolving Credit Agreement and the other transaction documents).</span></div> 150000000 P5Y 15000000 6200000 1100000 0.0010 0.0125 0.0250 0.0025 0.0150 0.0020 0.0025 0 3.50 4.00 Stock-Based Compensation<div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vericel Corporation 2022 Omnibus Incentive Plan (“2022 Plan”) was approved on April 27, 2022, and provides incentives through the grant of stock options, stock appreciation rights, restricted stock awards and restricted stock units. The exercise price of stock options granted under the 2022 Plan shall not be less than the fair market value of the Company’s common stock on the date of grant. The 2022 Plan replaced the 1992 Stock Option Plan, the 2001 Stock Option Plan, the Amended and Restated 2004 Equity Incentive Plan, the 2009 Second Amended and Restated Omnibus Incentive Plan, the 2017 Omnibus Incentive Plan, and the Amended and Restated 2019 Omnibus Incentive Plan (“Prior Plans”), and no new grants have been granted under the Prior Plans after approval of the 2022 Plan. However, the expiration or forfeiture of options previously granted under the Prior Plans will increase the number of shares available for issuance under the 2022 Plan.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Compensation Expense</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.077%"><tr><td style="width:1.0%"/><td style="width:63.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.040%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,731 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,531 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service-Based Stock Options</span></div><div style="text-align:justify;text-indent:6.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2023 and 2022, the Company granted service-based options to purchase common stock of 467,957 and 993,589, respectively. The weighted-average grant-date fair value of service-based options granted during the three months ended March 31, 2023 and 2022 was $18.00 and $20.99 per option, respectively. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units </span></div>During the three months ended March 31, 2023 and 2022, the Company granted 496,505 and 343,022 restricted stock units, respectively. The weighted-average grant-date fair value of restricted stock units granted during the three months ended March 31, 2023 and 2022 was $29.82 and $34.97 per unit, respectively. <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash stock-based compensation expense (service-based stock options, restricted stock units and employee stock purchase plan) is summarized in the following table:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.077%"><tr><td style="width:1.0%"/><td style="width:63.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.040%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total non-cash stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,731 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,531 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 885000 1118000 977000 1350000 6869000 7063000 8731000 9531000 467957 993589 18.00 20.99 496505 343022 29.82 34.97 Net Loss Per Common Share<div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net loss per common share is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.608%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.609%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,091)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from diluted net loss per common share:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of net loss per common share is presented below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.608%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.609%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in thousands, except per share amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,495)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,091)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,985 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive stock options and restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,387 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic loss per common share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.16)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.15)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive shares excluded from diluted net loss per common share:</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,918 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">954 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> -7495000 -7091000 47387000 46985000 0 0 47387000 46985000 -0.16 -0.15 -0.16 -0.15 6918000 6479000 954000 625000 NexoBrid License and Supply Agreements <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2019, the Company entered into exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America. NexoBrid is a topically-administered biological product, which was approved by the FDA on December 28, 2022 for commercial use in the U.S. NexoBrid contains proteolytic enzymes and is indicated for the removal of eschar in adults with deep partial-thickness and/or full thickness thermal burns.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the license agreement, following the FDA approval of NexoBrid, MediWound transferred the BLA to Vericel effective February 20, 2023. Both MediWound and Vericel, under the supervision of a Central Steering Committee comprised of members of both companies will continue to guide the development of NexoBrid in North America (the “Central Steering Committee”). NexoBrid is approved in the European Union (“EU”) and other international markets and has been designated as an orphan biologic in the U.S., EU and other international markets.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, the Company paid MediWound $17.5 million in consideration for the license, which was recorded as research and development expense during 2019. Pursuant to the terms of the license agreement, in February 2023, the Company tendered to MediWound a $7.5 million regulatory milestone payment following the FDA’s BLA approval of NexoBrid on December 28, 2022. The Company recorded the $7.5 million milestone payment for the licensing rights to commercially sell NexoBrid in the U.S., as an intangible asset (see Note 4, “Selected Balance Sheet Components” for further details).</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is additionally obligated to pay MediWound up to $125.0 million, which is contingent upon meeting certain sales milestones. The first sales milestone payment of $7.5 million would be triggered when annual net sales of NexoBrid or improvements to it in North America exceed $75.0 million. As of March 31, 2023, the sales milestone payments are not yet probable and therefore, not recorded as a liability. The Company also will pay MediWound tiered royalties on net sales ranging from mid-high single-digit to mid-teen percentages, subject to customary reductions. Pursuant to the terms of the Company’s supply agreement with MediWound, MediWound will manufacture NexoBrid for the Company on a unit price basis, which may be increased pursuant to the terms of the supply agreement. MediWound is obligated to supply the Company with NexoBrid for sale in North America on an exclusive basis for the first five years of the term of the supply agreement. Under the supply agreement, the Company possesses the option to extend the initial term of the agreement by an additional 24 months, which it did in May 2022. After the exclusivity period or upon supply failure, the Company will be permitted to establish an alternate source of supply.</span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, beginning in 2020 BARDA procured quantities of NexoBrid from MediWound for use as a medical countermeasure in the event of a mass casualty emergency in the U.S. involving thermal burns. The initial, quarterly, procurement of NexoBrid by BARDA under its agreement with MediWound completed during the third quarter of 2022. As a part of BARDA’s commitment to procure NexoBrid, the Company has received a percentage of gross profit for sales directly to BARDA. As of March 31, 2023, the Company did not hold a direct contract or distribution agreement with BARDA, or take title to the product procured by BARDA.</span></div><div style="text-align:justify;text-indent:13.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 9, 2023, MediWound announced BARDA’s award of additional funding under the parties’ existing agreement, $3 million of which will support the replacement of NexoBrid, previously procured for emergency response preparedness, which has since expired. Pursuant to the terms of the Company’s license agreement with MediWound, the Company would recognize revenue based on a percentage of gross profits, minus a percentage of net sales, on any sales of NexoBrid directly to BARDA, upon delivery, pursuant to this additional award.</span></div> 17500000 7500000 7500000 125000000 7500000 75000000 P5Y P24M 3000000 Commitments and Contingencies <div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company could be a party to various legal proceedings arising in the ordinary course of business. The costs and outcome of litigation, regulatory, investigatory or other proceedings cannot be predicted with certainty, and some lawsuits, claims, actions or proceedings may be disposed of unfavorably to the Company and could have a material adverse effect on the Company’s results of operations or financial condition. In addition, intellectual property disputes often have a risk of injunctive relief which, if imposed against the Company, could materially and adversely affect its financial condition or results of operations. If a matter is both probable to result in material liability and the amount of loss can be reasonably estimated, the Company estimates and discloses the possible material loss or range of loss. If such loss is not probable or cannot be reasonably estimated, a liability is not recorded in its condensed consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2023, the Company has no material ongoing litigation in which the Company was a party or any material ongoing regulatory or other proceedings and had no knowledge of any investigations by government or regulatory authorities in which the Company is a target that could have a material adverse effect on its current business.</span></div> Subsequent Events In April 2023, in connection with the Burlington Lease, the Company entered into a construction escrow agreement (the “Construction Escrow Agreement”) with the facility’s landlord and an escrow agent. Pursuant to the terms of the Construction Escrow Agreement, in April 2023, the Company began funding into an escrow account maintained by the escrow agent a portion of its share of tenant improvement construction costs at the facility, which will be designated as restricted cash. At the same time, the facility’s landlord began funding a portion of its tenant improvement allowance through a separate escrow account. To date, the Company has transferred into its escrow account 50% of its required cost amount, or approximately $28.3 million. The Company anticipates funding the remaining 50% of its required cost amount in late 2023 or early 2024. Additionally, and in order to support the expansion of the Company’s autologous cell manufacturing operations at the new facility in Burlington, the Company plans to invest in the acquisition and installation of certain specialized manufacturing and laboratory equipment. 0.50 28300000 0.50 EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 158 229 1 false 55 0 false 10 false false R1.htm 0000001 - Document - Cover Sheet http://vcel.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 0000008 - Disclosure - Organization Sheet http://vcel.com/role/Organization Organization Notes 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation Sheet http://vcel.com/role/BasisofPresentation Basis of Presentation Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Sheet http://vcel.com/role/Revenue Revenue Notes 10 false false R11.htm 0000011 - Disclosure - Selected Balance Sheet Components Sheet http://vcel.com/role/SelectedBalanceSheetComponents Selected Balance Sheet Components Notes 11 false false R12.htm 0000012 - Disclosure - Leases Sheet http://vcel.com/role/Leases Leases Notes 12 false false R13.htm 0000013 - Disclosure - Revolving Credit Agreement Sheet http://vcel.com/role/RevolvingCreditAgreement Revolving Credit Agreement Notes 13 false false R14.htm 0000014 - Disclosure - Stock-Based Compensation Sheet http://vcel.com/role/StockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 0000015 - Disclosure - Investments Sheet http://vcel.com/role/Investments Investments Notes 15 false false R16.htm 0000016 - Disclosure - Fair Value Measurements Sheet http://vcel.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 0000017 - Disclosure - Net Loss Per Common Share Sheet http://vcel.com/role/NetLossPerCommonShare Net Loss Per Common Share Notes 17 false false R18.htm 0000018 - Disclosure - NexoBrid License and Supply Agreements Sheet http://vcel.com/role/NexoBridLicenseandSupplyAgreements NexoBrid License and Supply Agreements Notes 18 false false R19.htm 0000019 - Disclosure - Commitments and Contingencies Sheet http://vcel.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 19 false false R20.htm 0000020 - Disclosure - Subsequent Events Sheet http://vcel.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 0000021 - Disclosure - Basis of Presentation (Policies) Sheet http://vcel.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 21 false false R22.htm 0000022 - Disclosure - Revenue (Tables) Sheet http://vcel.com/role/RevenueTables Revenue (Tables) Tables http://vcel.com/role/Revenue 22 false false R23.htm 0000023 - Disclosure - Selected Balance Sheet Components (Tables) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsTables Selected Balance Sheet Components (Tables) Tables http://vcel.com/role/SelectedBalanceSheetComponents 23 false false R24.htm 0000024 - Disclosure - Leases (Tables) Sheet http://vcel.com/role/LeasesTables Leases (Tables) Tables http://vcel.com/role/Leases 24 false false R25.htm 0000025 - Disclosure - Stock-Based Compensation (Tables) Sheet http://vcel.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://vcel.com/role/StockBasedCompensation 25 false false R26.htm 0000026 - Disclosure - Investments (Tables) Sheet http://vcel.com/role/InvestmentsTables Investments (Tables) Tables http://vcel.com/role/Investments 26 false false R27.htm 0000027 - Disclosure - Fair Value Measurements (Tables) Sheet http://vcel.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://vcel.com/role/FairValueMeasurements 27 false false R28.htm 0000028 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://vcel.com/role/NetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://vcel.com/role/NetLossPerCommonShare 28 false false R29.htm 0000029 - Disclosure - Organization (Details) Sheet http://vcel.com/role/OrganizationDetails Organization (Details) Details http://vcel.com/role/Organization 29 false false R30.htm 0000030 - Disclosure - Revenue - Narrative (Details) Sheet http://vcel.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 30 false false R31.htm 0000031 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Details) Sheet http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails Revenue - Summary of Disaggregation of Revenue (Details) Details 31 false false R32.htm 0000032 - Disclosure - Selected Balance Sheet Components - Summary of inventory (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails Selected Balance Sheet Components - Summary of inventory (Details) Details 32 false false R33.htm 0000033 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails Selected Balance Sheet Components - Schedule of property and equipment, net (Details) Details 33 false false R34.htm 0000034 - Disclosure - Selected Balance Sheet Components - Narrative (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails Selected Balance Sheet Components - Narrative (Details) Details 34 false false R35.htm 0000035 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details) Details 35 false false R36.htm 0000036 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details) Details 36 false false R37.htm 0000037 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details) Sheet http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails Selected Balance Sheet Components - Schedule of accrued expenses (Details) Details 37 false false R38.htm 0000038 - Disclosure - Leases - Narrative (Details) Sheet http://vcel.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 38 false false R39.htm 0000039 - Disclosure - Leases - Summary of assets and liabilities (Details) Sheet http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails Leases - Summary of assets and liabilities (Details) Details 39 false false R40.htm 0000040 - Disclosure - Revolving Credit Agreement (Details) Sheet http://vcel.com/role/RevolvingCreditAgreementDetails Revolving Credit Agreement (Details) Details http://vcel.com/role/RevolvingCreditAgreement 40 false false R41.htm 0000041 - Disclosure - Stock-Based Compensation - Expense (Details) Sheet http://vcel.com/role/StockBasedCompensationExpenseDetails Stock-Based Compensation - Expense (Details) Details 41 false false R42.htm 0000042 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://vcel.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 42 false false R43.htm 0000043 - Disclosure - Investments (Details) Sheet http://vcel.com/role/InvestmentsDetails Investments (Details) Details http://vcel.com/role/InvestmentsTables 43 false false R44.htm 0000044 - Disclosure - Fair Value Measurements (Details) Sheet http://vcel.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://vcel.com/role/FairValueMeasurementsTables 44 false false R45.htm 0000045 - Disclosure - Net Loss Per Common Share (Details) Sheet http://vcel.com/role/NetLossPerCommonShareDetails Net Loss Per Common Share (Details) Details http://vcel.com/role/NetLossPerCommonShareTables 45 false false R46.htm 0000046 - Disclosure - NexoBrid License and Supply Agreements (Details) Sheet http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails NexoBrid License and Supply Agreements (Details) Details http://vcel.com/role/NexoBridLicenseandSupplyAgreements 46 false false R47.htm 0000047 - Disclosure - Subsequent Events (Details) Sheet http://vcel.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://vcel.com/role/SubsequentEvents 47 false false All Reports Book All Reports vcel-20230331.htm ex311ceocertificationq12023.htm ex312cfocertificationq12023.htm ex321ceoandcfosoxcertifica.htm vcel-20230331.xsd vcel-20230331_cal.xml vcel-20230331_def.xml vcel-20230331_lab.xml vcel-20230331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vcel-20230331.htm": { "axisCustom": 0, "axisStandard": 23, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 487, "http://xbrl.sec.gov/dei/2022": 29 }, "contextCount": 158, "dts": { "calculationLink": { "local": [ "vcel-20230331_cal.xml" ] }, "definitionLink": { "local": [ "vcel-20230331_def.xml" ] }, "inline": { "local": [ "vcel-20230331.htm" ] }, "labelLink": { "local": [ "vcel-20230331_lab.xml" ] }, "presentationLink": { "local": [ "vcel-20230331_pre.xml" ] }, "schema": { "local": [ "vcel-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 393, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 6, "http://xbrl.sec.gov/dei/2022": 5, "total": 11 }, "keyCustom": 35, "keyStandard": 194, "memberCustom": 12, "memberStandard": 40, "nsprefix": "vcel", "nsuri": "http://vcel.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://vcel.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Revenue", "menuCat": "Notes", "order": "10", "role": "http://vcel.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Selected Balance Sheet Components", "menuCat": "Notes", "order": "11", "role": "http://vcel.com/role/SelectedBalanceSheetComponents", "shortName": "Selected Balance Sheet Components", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Leases", "menuCat": "Notes", "order": "12", "role": "http://vcel.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Revolving Credit Agreement", "menuCat": "Notes", "order": "13", "role": "http://vcel.com/role/RevolvingCreditAgreement", "shortName": "Revolving Credit Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "14", "role": "http://vcel.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Investments", "menuCat": "Notes", "order": "15", "role": "http://vcel.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Fair Value Measurements", "menuCat": "Notes", "order": "16", "role": "http://vcel.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Net Loss Per Common Share", "menuCat": "Notes", "order": "17", "role": "http://vcel.com/role/NetLossPerCommonShare", "shortName": "Net Loss Per Common Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - NexoBrid License and Supply Agreements", "menuCat": "Notes", "order": "18", "role": "http://vcel.com/role/NexoBridLicenseandSupplyAgreements", "shortName": "NexoBrid License and Supply Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "19", "role": "http://vcel.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShortTermInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Subsequent Events", "menuCat": "Notes", "order": "20", "role": "http://vcel.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Basis of Presentation (Policies)", "menuCat": "Policies", "order": "21", "role": "http://vcel.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskCreditRisk", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Revenue (Tables)", "menuCat": "Tables", "order": "22", "role": "http://vcel.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Selected Balance Sheet Components (Tables)", "menuCat": "Tables", "order": "23", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsTables", "shortName": "Selected Balance Sheet Components (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Leases (Tables)", "menuCat": "Tables", "order": "24", "role": "http://vcel.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "25", "role": "http://vcel.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Investments (Tables)", "menuCat": "Tables", "order": "26", "role": "http://vcel.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "27", "role": "http://vcel.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Net Loss Per Common Share (Tables)", "menuCat": "Tables", "order": "28", "role": "http://vcel.com/role/NetLossPerCommonShareTables", "shortName": "Net Loss Per Common Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfProducts", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Organization (Details)", "menuCat": "Details", "order": "29", "role": "http://vcel.com/role/OrganizationDetails", "shortName": "Organization (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfProducts", "reportCount": 1, "unique": true, "unitRef": "product", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfContractedSpecialtyPharmacies", "reportCount": 1, "unique": true, "unitRef": "pharmacy", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Revenue - Narrative (Details)", "menuCat": "Details", "order": "30", "role": "http://vcel.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "vcel:NumberOfContractedSpecialtyPharmacies", "reportCount": 1, "unique": true, "unitRef": "pharmacy", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Revenue - Summary of Disaggregation of Revenue (Details)", "menuCat": "Details", "order": "31", "role": "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails", "shortName": "Revenue - Summary of Disaggregation of Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i2808e06489b94432b3c57920d76f693a_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Selected Balance Sheet Components - Summary of inventory (Details)", "menuCat": "Details", "order": "32", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails", "shortName": "Selected Balance Sheet Components - Summary of inventory (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Selected Balance Sheet Components - Schedule of property and equipment, net (Details)", "menuCat": "Details", "order": "33", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails", "shortName": "Selected Balance Sheet Components - Schedule of property and equipment, net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Selected Balance Sheet Components - Narrative (Details)", "menuCat": "Details", "order": "34", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "shortName": "Selected Balance Sheet Components - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details)", "menuCat": "Details", "order": "35", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "shortName": "Selected Balance Sheet Components -Schedule of finite-lived intangible assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i082f559568114ea1a18b493c29f5f172_D20230101-20230331", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details)", "menuCat": "Details", "order": "36", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails", "shortName": "Selected Balance Sheet Components -Schedule of finite-lived intangible assets, future amortization expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "iffa92a077d564eea9066b1ccf2a5b0e3_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Selected Balance Sheet Components - Schedule of accrued expenses (Details)", "menuCat": "Details", "order": "37", "role": "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails", "shortName": "Selected Balance Sheet Components - Schedule of accrued expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:ShortTermLeaseCost", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Leases - Narrative (Details)", "menuCat": "Details", "order": "38", "role": "http://vcel.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ShortTermLeaseCost", "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Leases - Summary of assets and liabilities (Details)", "menuCat": "Details", "order": "39", "role": "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails", "shortName": "Leases - Summary of assets and liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "vcel:AssetsAndLiabilitiesLeasesTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:FinanceLeaseRightOfUseAsset", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i52b4a6d7c28f4b8dba7c5c92688e3dcd_I20220729", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Revolving Credit Agreement (Details)", "menuCat": "Details", "order": "40", "role": "http://vcel.com/role/RevolvingCreditAgreementDetails", "shortName": "Revolving Credit Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i52b4a6d7c28f4b8dba7c5c92688e3dcd_I20220729", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:LettersOfCreditOutstandingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i797d83bfc03e4296914c68fd97c3145f_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Stock-Based Compensation - Expense (Details)", "menuCat": "Details", "order": "41", "role": "http://vcel.com/role/StockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i797d83bfc03e4296914c68fd97c3145f_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "ie6f1126caa2b4cd089f3e2b7b3106cf3_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Stock-Based Compensation - Narrative (Details)", "menuCat": "Details", "order": "42", "role": "http://vcel.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "ie6f1126caa2b4cd089f3e2b7b3106cf3_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Investments (Details)", "menuCat": "Details", "order": "43", "role": "http://vcel.com/role/InvestmentsDetails", "shortName": "Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i44b47d0e4f1f40c889e430ff495a2e1c_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Fair Value Measurements (Details)", "menuCat": "Details", "order": "44", "role": "http://vcel.com/role/FairValueMeasurementsDetails", "shortName": "Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "if811954285bd4c31af7681afe4d1a092_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Net Loss Per Common Share (Details)", "menuCat": "Details", "order": "45", "role": "http://vcel.com/role/NetLossPerCommonShareDetails", "shortName": "Net Loss Per Common Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i4df8784fcb114bc0b38bd41aca4f1d41_I20190531", "decimals": "-5", "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - NexoBrid License and Supply Agreements (Details)", "menuCat": "Details", "order": "46", "role": "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "shortName": "NexoBrid License and Supply Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i4df8784fcb114bc0b38bd41aca4f1d41_I20190531", "decimals": "-5", "first": true, "lang": "en-US", "name": "vcel:LicenseAgreementConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i6a2e630f0cce40cf8ba2a82883ebd496_I20230430", "decimals": "2", "first": true, "lang": "en-US", "name": "vcel:EscrowDepositPercentContributed", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Subsequent Events (Details)", "menuCat": "Details", "order": "47", "role": "http://vcel.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i6a2e630f0cce40cf8ba2a82883ebd496_I20230430", "decimals": "2", "first": true, "lang": "en-US", "name": "vcel:EscrowDepositPercentContributed", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "5", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i6f75dcf1336f4cd38860b9abb09cbd81_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "menuCat": "Statements", "order": "6", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i6f75dcf1336f4cd38860b9abb09cbd81_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "7", "role": "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Organization", "menuCat": "Notes", "order": "8", "role": "http://vcel.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "9", "role": "http://vcel.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vcel-20230331.htm", "contextRef": "i792ee0b397da4d9b906bffc39b5d005d_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccounting", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 55, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r529" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://vcel.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r155", "r156", "r263", "r287", "r493", "r495" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r247", "r248", "r249", "r250", "r310", "r454", "r468", "r488", "r489", "r506", "r517", "r522", "r564", "r580", "r581", "r582", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r247", "r248", "r249", "r250", "r310", "r454", "r468", "r488", "r489", "r506", "r517", "r522", "r564", "r580", "r581", "r582", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r207", "r455", "r507", "r521", "r559", "r560", "r566", "r588" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r207", "r455", "r507", "r521", "r559", "r560", "r566", "r588" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r247", "r248", "r249", "r250", "r303", "r310", "r338", "r339", "r340", "r430", "r454", "r468", "r488", "r489", "r506", "r517", "r522", "r558", "r564", "r581", "r582", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r247", "r248", "r249", "r250", "r303", "r310", "r338", "r339", "r340", "r430", "r454", "r468", "r488", "r489", "r506", "r517", "r522", "r558", "r564", "r581", "r582", "r583", "r584", "r585" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r487", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]", "terseLabel": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r487", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]", "terseLabel": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r155", "r156", "r263", "r287", "r494", "r495" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r11", "r520" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r210", "r211" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $47 and $47, respectively)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r40" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Bonus related compensation" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedInsuranceCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Insurance, Current", "terseLabel": "Insurance reimbursement-related liabilities" } } }, "localname": "AccruedInsuranceCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r20", "r21", "r22", "r134", "r465", "r476", "r480" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r19", "r22", "r84", "r420", "r471", "r472", "r536", "r537", "r538", "r545", "r546", "r547" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r119", "r120", "r121", "r122", "r123", "r161", "r162", "r163", "r164", "r173", "r213", "r214", "r221", "r222", "r223", "r224", "r225", "r226", "r346", "r347", "r348", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r397", "r398", "r402", "r403", "r404", "r405", "r415", "r416", "r417", "r418", "r419", "r420", "r457", "r458", "r459", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Restricted stock withheld for employee tax remittance" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r77", "r78", "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash flows from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r342" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total non-cash stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r135", "r212", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent": { "auth_ref": [ "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on receivable, classified as other and current.", "label": "Allowance for Credit Loss, Receivable, Other, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulOtherReceivablesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r25", "r282", "r400", "r542" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r39", "r55", "r59" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive shares excluded from the calculation of diluted earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r39", "r61" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Impairments of assets" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r97", "r111", "r132", "r154", "r198", "r201", "r205", "r220", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r357", "r359", "r381", "r520", "r562", "r563", "r578" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS", "verboseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r125", "r138", "r154", "r220", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r357", "r359", "r381", "r520", "r562", "r563", "r578" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r87" ], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r216", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "terseLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r51", "r215", "r233", "r461" ], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Estimated Fair Value", "verboseLabel": "Debt securities, fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r50", "r128", "r233" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Long-term investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Classified as:" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]", "terseLabel": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccounting": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccounting", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r42", "r43", "r44" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Additions to property and equipment included in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r41", "r127", "r491" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://vcel.com/role/FairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r36", "r41", "r45" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash at end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Reconciliation of amounts within the condensed consolidated balance sheets:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r36", "r89" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r48", "r168" ], "lang": { "en-us": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]", "terseLabel": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r48", "r168" ], "lang": { "en-us": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]", "terseLabel": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A change from one acceptable accounting method to another based upon a revision in estimated future benefits or obligations.", "label": "Change in Accounting Method Accounted for as Change in Estimate [Member]", "terseLabel": "Change in estimates related to prior periods" } } }, "localname": "ChangeInAccountingMethodAccountedForAsChangeInEstimateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r568", "r571" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r17", "r103", "r114" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r65", "r245", "r246", "r485", "r561" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r545", "r546", "r570" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r3", "r69" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Ending balance (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r3", "r520" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, no par value; shares authorized \u2014 75,000; shares issued and\u00a0outstanding 47,507 and 47,253, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r23", "r140", "r142", "r149", "r462", "r466" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r108", "r191" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingAxis": { "auth_ref": [ "r510", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by basis of pricing for contract representing right to consideration in exchange for good or service transferred to customer.", "label": "Contract with Customer, Basis of Pricing [Axis]", "terseLabel": "Contract with Customer, Basis of Pricing [Axis]" } } }, "localname": "ContractWithCustomerBasisOfPricingAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerBasisOfPricingDomain": { "auth_ref": [ "r510", "r566" ], "lang": { "en-us": { "role": { "documentation": "Basis of pricing for contract with customer. Includes, but is not limited to, fixed-price and time-and-materials contracts.", "label": "Contract with Customer, Basis of Pricing [Domain]", "terseLabel": "Contract with Customer, Basis of Pricing [Domain]" } } }, "localname": "ContractWithCustomerBasisOfPricingDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerSalesChannelAxis": { "auth_ref": [ "r513", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by sales channel for delivery of good or service in contract with customer.", "label": "Contract with Customer, Sales Channel [Axis]", "terseLabel": "Contract with Customer, Sales Channel [Axis]" } } }, "localname": "ContractWithCustomerSalesChannelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerSalesChannelDomain": { "auth_ref": [ "r513", "r566" ], "lang": { "en-us": { "role": { "documentation": "Sales channel for delivery of good or service in contract with customer. Includes, but is not limited to, directly to consumer and through intermediary.", "label": "Contract with Customer, Sales Channel [Domain]", "terseLabel": "Contract with Customer, Sales Channel [Domain]" } } }, "localname": "ContractWithCustomerSalesChannelDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r514", "r516", "r589" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNoteSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).", "label": "Corporate Note Securities [Member]", "terseLabel": "Corporate notes" } } }, "localname": "CorporateNoteSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r27", "r455" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r68", "r153", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r276", "r283", "r284", "r286" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Revolving Credit Agreement" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (in percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r16", "r70", "r71", "r72", "r73", "r90", "r91", "r93", "r107", "r157", "r260", "r261", "r262", "r263", "r264", "r266", "r272", "r273", "r274", "r275", "r277", "r278", "r279", "r280", "r281", "r282", "r285", "r401", "r501", "r502", "r503", "r504", "r505", "r543" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "auth_ref": [ "r217", "r233", "r236", "r237" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Credit Losses" } } }, "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of fair value of securities, not including cash" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r92", "r565" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Debt issuance costs, net" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r39", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r39", "r197" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r299", "r507", "r508", "r509", "r510", "r511", "r512", "r513" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r315", "r343", "r344", "r345", "r349", "r518" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r150", "r165", "r166", "r167", "r168", "r169", "r174", "r176", "r181", "r182", "r183", "r187", "r371", "r372", "r463", "r467", "r497" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "netLabel": "Basic loss per common share (in USD per share)", "terseLabel": "Basic (in USD per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r150", "r165", "r166", "r167", "r168", "r169", "r176", "r181", "r182", "r183", "r187", "r371", "r372", "r463", "r467", "r497" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "netLabel": "Diluted loss per common share (in USD per share)", "terseLabel": "Diluted (in USD per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r184", "r185", "r186", "r188" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Common Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r14" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee related accruals" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r69", "r121", "r143", "r144", "r145", "r158", "r159", "r160", "r162", "r170", "r172", "r189", "r224", "r289", "r346", "r347", "r348", "r352", "r353", "r370", "r390", "r391", "r392", "r393", "r394", "r395", "r420", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EscrowDeposit": { "auth_ref": [ "r102", "r486" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.", "label": "Escrow Deposit", "terseLabel": "Escrow deposit amount" } } }, "localname": "EscrowDeposit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Liabilities that are measured at fair value on a recurring basis" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r374", "r375", "r379" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r375", "r427", "r428", "r429", "r502", "r503", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r374", "r375", "r376", "r377", "r380" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r274", "r304", "r309", "r375", "r427", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level\u00a01" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r274", "r304", "r309", "r375", "r428", "r502", "r503", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level\u00a02" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r375", "r429", "r502", "r503", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.", "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of valuation of the company's investments and financial instruments that are measured at fair value on a recurring basis" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r274", "r304", "r305", "r306", "r307", "r308", "r309", "r427", "r428", "r429", "r502", "r503", "r514", "r515", "r516" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r378", "r380" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r409", "r411", "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease expense (less than)" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r407" ], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.", "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r406" ], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 2.0, "parentTag": "vcel_RightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization": { "auth_ref": [ "r573" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, before Accumulated Amortization", "terseLabel": "Financing right-of-use lease" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes finance lease right-of-use asset.", "label": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]" } } }, "localname": "FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r218", "r219", "r228", "r229", "r230", "r231", "r232", "r234", "r235", "r238", "r285", "r288", "r361", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r500", "r551", "r552", "r553", "r598", "r599", "r600", "r601", "r602", "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful Live (in years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r130", "r241" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r60" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "terseLabel": "Remainder of 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r60" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "terseLabel": "2027" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r60" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r60" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r239", "r240", "r241", "r242", "r456", "r460" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r58", "r460" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Cost" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r58", "r456" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Intangible assets, net", "totalLabel": "Total" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FixedPriceContractMember": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which amount of consideration is fixed.", "label": "Fixed-Price Contract [Member]", "terseLabel": "Contract rate" } } }, "localname": "FixedPriceContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture, fixtures and office equipment" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r26", "r154", "r198", "r200", "r204", "r206", "r220", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r381", "r499", "r562" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r38" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r38" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r38" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r541" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r38" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Shareholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r177", "r178", "r179", "r183", "r314" ], "calculation": { "http://vcel.com/role/NetLossPerCommonShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "terseLabel": "Effect of dilutive stock options and restricted stock units (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r92", "r105", "r146", "r196", "r399" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r531" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r136", "r492", "r520" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "totalLabel": "Total inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Net [Abstract]", "terseLabel": "Inventory:" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r533" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r532" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsSummaryofinventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r29", "r195" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Short term investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r54", "r96", "r106", "r117", "r490" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Issuance of letters of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r13", "r154", "r220", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r358", "r359", "r360", "r381", "r498", "r562", "r578", "r579" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r99", "r113", "r520", "r544", "r554", "r572" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and shareholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r15", "r126", "r154", "r220", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r358", "r359", "r360", "r381", "r520", "r562", "r578", "r579" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:", "verboseLabel": "Current" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r80" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r1", "r98", "r109" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-Term Line of Credit", "terseLabel": "Outstanding borrowings" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Line of credit facility, commitment fee (in percent)" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r16", "r67" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and equipment" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Marketable Securities [Line Items]", "terseLabel": "Marketable Securities [Line Items]" } } }, "localname": "MarketableSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in marketable security.", "label": "Marketable Securities [Table]", "terseLabel": "Marketable Securities [Table]" } } }, "localname": "MarketableSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r190", "r192" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r152" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r152" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r36", "r37", "r40" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r24", "r40", "r104", "r116", "r124", "r139", "r141", "r145", "r154", "r161", "r165", "r166", "r167", "r168", "r171", "r172", "r180", "r198", "r200", "r204", "r206", "r220", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r372", "r381", "r499", "r562" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "negatedLabel": "Net loss", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY", "http://vcel.com/role/NetLossPerCommonShareDetails", "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r30" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r198", "r200", "r204", "r206", "r499" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r575" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r407" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 3.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating", "verboseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r407" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_LeaseLiabilityNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r406" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": 1.0, "parentTag": "vcel_RightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating", "verboseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r542" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash lease costs" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r137", "r520" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r131" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r81", "r82", "r83" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain (loss) on investment", "verboseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r14", "r520" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r40" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r31" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r151" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Payments on employee\u2019s behalf for taxes related to vesting of restricted stock unit awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r33" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchases of intangible assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r33" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Expenditures for property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "auth_ref": [ "r34" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Payments to Acquire Short-Term Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r35" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from common stock issuance" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r539", "r540" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "auth_ref": [ "r32" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.", "label": "Proceeds from Sale, Maturity and Collection of Short-Term Investments", "terseLabel": "Sales and maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r556", "r574", "r577" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, Accumulated Depreciation and Amortization", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r557", "r577" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r530", "r555", "r573" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, before Accumulated Depreciation and Amortization", "totalLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r63", "r129" ], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]", "verboseLabel": "Property and equipment, net:" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r79", "r118", "r586" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r41", "r45", "r484" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r74", "r112", "r475", "r480", "r520" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r121", "r158", "r159", "r160", "r162", "r170", "r172", "r224", "r346", "r347", "r348", "r352", "r353", "r370", "r471", "r473" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r193", "r194", "r199", "r202", "r203", "r207", "r208", "r209", "r298", "r299", "r455" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Product sales, net" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueNotFromContractWithCustomerOther": { "auth_ref": [ "r147" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue that is not accounted for under Topic 606, classified as other.", "label": "Revenue Not from Contract with Customer, Other", "terseLabel": "Other revenue", "verboseLabel": "NexoBrid revenue" } } }, "localname": "RevenueNotFromContractWithCustomerOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r148", "r154", "r193", "r194", "r199", "r202", "r203", "r207", "r208", "r209", "r220", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r381", "r464", "r562" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving credit facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r413", "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use asset and lease liability recognized" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SalesChannelDirectlyToConsumerMember": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred directly to consumer.", "label": "Sales Channel, Directly to Consumer [Member]", "terseLabel": "Directly to consumer" } } }, "localname": "SalesChannelDirectlyToConsumerMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SalesChannelThroughIntermediaryMember": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred through intermediary.", "label": "Sales Channel, Through Intermediary [Member]", "terseLabel": "Through Intermediary" } } }, "localname": "SalesChannelThroughIntermediaryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of net loss attributable to common shareholders and share data used in the basic and diluted earnings per share computations using the two class method" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NetLossPerCommonShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r75", "r76" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of non-cash stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r56", "r57", "r456" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r8", "r9", "r10" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsNarrativeDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsDetails", "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r94", "r95" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r311", "r313", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of finite-lived intangible assets, future amortization expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "SOFR" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r28" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r38" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Restricted stock units granted (shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Weighted-average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r333" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant-date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails", "http://vcel.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Restricted stock withheld for employee tax remittance (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r100", "r101", "r110", "r534" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestmentsMember": { "auth_ref": [ "r481", "r482", "r483", "r523" ], "lang": { "en-us": { "role": { "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.", "label": "Short-Term Investments [Member]", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r412", "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease costs (less than)" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r18", "r69", "r121", "r143", "r144", "r145", "r158", "r159", "r160", "r162", "r170", "r172", "r189", "r224", "r289", "r346", "r347", "r348", "r352", "r353", "r370", "r390", "r391", "r392", "r393", "r394", "r395", "r420", "r471", "r472", "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r158", "r159", "r160", "r189", "r455" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r2", "r3", "r69", "r74" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Shares issued under the Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r2", "r3", "r69", "r74" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of stock for restricted stock unit vesting (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r2", "r3", "r69", "r74", "r324" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "verboseLabel": "Stock option exercises (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r2", "r3", "r69", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Shares issued under the Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r18", "r69", "r74" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock option exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r3", "r5", "r6", "r49", "r520", "r544", "r554", "r572" ], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Shareholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r396", "r422" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails", "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r396", "r422" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r396", "r422" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails", "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r396", "r422" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails", "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r421", "r423" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Selected Balance Sheet Components" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TimeAndMaterialsContractMember": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which amount of consideration is based on time and materials consumed.", "label": "Time-and-Materials Contract [Member]", "terseLabel": "Time-and-materials contract" } } }, "localname": "TimeAndMaterialsContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r218", "r219", "r285", "r288", "r361", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r551", "r552", "r553", "r598", "r599", "r600", "r601", "r602", "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r119", "r120", "r121", "r122", "r123", "r161", "r162", "r163", "r164", "r173", "r213", "r214", "r221", "r222", "r223", "r224", "r225", "r226", "r346", "r347", "r348", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r397", "r398", "r402", "r403", "r404", "r405", "r415", "r416", "r417", "r418", "r419", "r420", "r457", "r458", "r459", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Indicates type of cost from product sold and service rendered.", "label": "Cost, Product and Service [Extensible Enumeration]", "terseLabel": "Cost, Product and Service [Extensible List]" } } }, "localname": "TypeOfCostGoodOrServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_TypeOfRevenueExtensibleList": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.", "label": "Revenue, Product and Service [Extensible Enumeration]", "terseLabel": "Revenue, Product and Service [Extensible List]" } } }, "localname": "TypeOfRevenueExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r496", "r514", "r587" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government agency bonds" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentDebtSecuritiesMember": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by the United States government.", "label": "US Government Debt Securities [Member]", "terseLabel": "U.S. government securities" } } }, "localname": "USGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/FairValueMeasurementsDetails", "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r175", "r183" ], "calculation": { "http://vcel.com/role/NetLossPerCommonShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average common shares outstanding:", "verboseLabel": "Anti-dilutive shares excluded from diluted net loss per common share:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r174", "r183" ], "calculation": { "http://vcel.com/role/NetLossPerCommonShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://vcel.com/role/NetLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "vcel_A25NetworkDriveBurlingtonMassachusettsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "25 Network Drive, Burlington, Massachusetts Member", "label": "25 Network Drive, Burlington, Massachusetts [Member]", "terseLabel": "25 Network Drive, Burlington, Massachusetts" } } }, "localname": "A25NetworkDriveBurlingtonMassachusettsMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails", "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "vcel_AccruedExpensesOtherCurrent": { "auth_ref": [], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents other accrued expenses, current.", "label": "Accrued Expenses, Other, Current", "terseLabel": "Other accrued expenses" } } }, "localname": "AccruedExpensesOtherCurrent", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofaccruedexpensesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_AnnArborMichiganMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ann Arbor, Michigan", "label": "Ann Arbor, Michigan [Member]", "terseLabel": "Ann Arbor Michigan" } } }, "localname": "AnnArborMichiganMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "vcel_AssetsAndLiabilitiesLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Leases [Table Text Block]", "label": "Assets And Liabilities, Leases [Table Text Block]", "terseLabel": "Schedule of assets and liabilities" } } }, "localname": "AssetsAndLiabilitiesLeasesTableTextBlock", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "vcel_BiopsyKitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biopsy Kits [Member]", "label": "Biopsy Kits [Member]", "terseLabel": "Biopsy kits" } } }, "localname": "BiopsyKitsMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_ComputerEquipmentAndComputerSoftwareIntangibleAssetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and the collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.", "label": "Computer Equipment And Computer Software Intangible Asset [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentAndComputerSoftwareIntangibleAssetMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleofpropertyandequipmentnetDetails" ], "xbrltype": "domainItemType" }, "vcel_DebtInstrumentCovenantIncreaseOptionLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Increase Option, Leverage Ratio, Maximum", "terseLabel": "Increase option for leverage ratio" } } }, "localname": "DebtInstrumentCovenantIncreaseOptionLeverageRatioMaximum", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "pureItemType" }, "vcel_DebtInstrumentCovenantLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "terseLabel": "Leverage ratio" } } }, "localname": "DebtInstrumentCovenantLeverageRatioMaximum", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevolvingCreditAgreementDetails" ], "xbrltype": "pureItemType" }, "vcel_DebtSecuritiesAvailableForSaleContractualMaturityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-sale, Contractual Maturity Period", "label": "Debt Securities, Available-for-sale, Contractual Maturity Period", "terseLabel": "Remaining contractual maturity period" } } }, "localname": "DebtSecuritiesAvailableForSaleContractualMaturityPeriod", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "durationItemType" }, "vcel_EmployeeStockAndEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock And Employee Stock Option [Member]", "label": "Employee Stock And Employee Stock Option [Member]", "terseLabel": "Employee stock purchase plan and service-based stock options" } } }, "localname": "EmployeeStockAndEmployeeStockOptionMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/StockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "vcel_EpicelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Epicel [Member]", "label": "Epicel [Member]", "terseLabel": "Epicel" } } }, "localname": "EpicelMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_EscrowDepositPercentContributed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Deposit, Percent Contributed", "label": "Escrow Deposit, Percent Contributed", "terseLabel": "Percent contributed to escrow account" } } }, "localname": "EscrowDepositPercentContributed", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "vcel_EscrowDepositRemainingPercentToBeContributed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Escrow Deposit, Remaining Percent To Be Contributed", "label": "Escrow Deposit, Remaining Percent To Be Contributed", "terseLabel": "Remaining percent to be contributed to escrow account" } } }, "localname": "EscrowDepositRemainingPercentToBeContributed", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "vcel_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "auth_ref": [], "calculation": { "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "terseLabel": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/SelectedBalanceSheetComponentsScheduleoffinitelivedintangibleassetsfutureamortizationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "vcel_ImplantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Implants [Member]", "label": "Implants [Member]", "terseLabel": "MACI implants and kits" } } }, "localname": "ImplantsMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Lease Liabilities", "label": "Increase (Decrease) In Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseLiabilityNoncurrent": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease Liability Noncurrent", "label": "Lease Liability Noncurrent", "totalLabel": "Total leased liabilities" } } }, "localname": "LeaseLiabilityNoncurrent", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LeaseOptionToExtendTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Option To Extend Term", "label": "Lease Option To Extend Term", "terseLabel": "Lease option to extend term" } } }, "localname": "LeaseOptionToExtendTerm", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "vcel_LesseeLeaseCommencementRentPaymentStartDateTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Lease Commencement, Rent Payment Start Date, Term", "label": "Lessee, Lease Commencement, Rent Payment Start Date, Term", "terseLabel": "Rent start date, term" } } }, "localname": "LesseeLeaseCommencementRentPaymentStartDateTerm", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "vcel_LesseeOperatingLeaseAnnualLeaseIncreaseLimitPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Annual Lease Increase Limit, Percentage", "label": "Lessee, Operating Lease, Annual Lease Increase Limit, Percentage", "terseLabel": "Annual lease base rent square subject to increase percentage" } } }, "localname": "LesseeOperatingLeaseAnnualLeaseIncreaseLimitPercentage", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "vcel_LesseeOperatingLeaseAnnualLeasePerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Annual Lease Per Square Foot", "label": "Lessee, Operating Lease, Annual Lease Per Square Foot", "terseLabel": "Annual lease per square foot" } } }, "localname": "LesseeOperatingLeaseAnnualLeasePerSquareFoot", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_LesseeOperatingLeaseMonthlyContractualPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Monthly Contractual Payments", "label": "Lessee, Operating Lease, Monthly Contractual Payments", "terseLabel": "Monthly contractual lease payments" } } }, "localname": "LesseeOperatingLeaseMonthlyContractualPayments", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LesseeOperatingLeaseNumberOfRenewalOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Renewal Options", "label": "Lessee, Operating Lease, Number Of Renewal Options", "terseLabel": "Number of renewal options" } } }, "localname": "LesseeOperatingLeaseNumberOfRenewalOptions", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_LesseeOperatingLeaseTenantImprovementAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Tenant Improvement Allowance", "label": "Lessee, Operating Lease, Tenant Improvement Allowance", "terseLabel": "Tenant improvement allowance" } } }, "localname": "LesseeOperatingLeaseTenantImprovementAllowance", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LesseeOperatingLeaseTenantImprovementAllowancePerSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating Lease Tenant Improvement Allowance Per Square Foot", "label": "Lessee Operating Lease Tenant Improvement Allowance Per Square Foot", "terseLabel": "Tenant improvement allowance per square foot" } } }, "localname": "LesseeOperatingLeaseTenantImprovementAllowancePerSquareFoot", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_LetterOfCreditCashDeposit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Letter Of Credit Cash Deposit", "label": "Letter Of Credit Cash Deposit", "terseLabel": "Letter of credit cash deposit" } } }, "localname": "LetterOfCreditCashDeposit", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LetterOfCreditCashDepositLeaseYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Letter Of Credit Cash Deposit Lease Year Four", "label": "Letter Of Credit Cash Deposit Lease Year Four", "terseLabel": "Letter of credit cash deposit lease year six" } } }, "localname": "LetterOfCreditCashDepositLeaseYearFour", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LetterOfCreditCashDepositLeaseYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Letter Of Credit Cash Deposit Lease Year Three", "label": "Letter Of Credit Cash Deposit Lease Year Three", "terseLabel": "Letter of credit cash deposit lease year three" } } }, "localname": "LetterOfCreditCashDepositLeaseYearThree", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementAdditionalFunding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Additional Funding", "label": "License Agreement, Additional Funding", "terseLabel": "Additional funding" } } }, "localname": "LicenseAgreementAdditionalFunding", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Consideration", "label": "License Agreement, Consideration", "terseLabel": "Consideration payment for license" } } }, "localname": "LicenseAgreementConsideration", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Contingent Consideration", "label": "License Agreement, Contingent Consideration", "terseLabel": "Contingent consideration" } } }, "localname": "LicenseAgreementContingentConsideration", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementContingentConsiderationMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Contingent Consideration, Maximum", "label": "License Agreement, Contingent Consideration, Maximum", "terseLabel": "Maximum contingent consideration" } } }, "localname": "LicenseAgreementContingentConsiderationMaximum", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementInitialMilestoneSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Initial Milestone, Sales", "label": "License Agreement, Initial Milestone, Sales", "terseLabel": "Sales threshold for first milestone" } } }, "localname": "LicenseAgreementInitialMilestoneSales", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "vcel_LicenseAgreementSupplyAgreementRenewalTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Supply Agreement Renewal Term", "label": "License Agreement, Supply Agreement Renewal Term", "terseLabel": "Renewal term of supply agreement" } } }, "localname": "LicenseAgreementSupplyAgreementRenewalTerm", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "durationItemType" }, "vcel_LicenseAgreementSupplyAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement, Supply Agreement Term", "label": "License Agreement, Supply Agreement Term", "terseLabel": "Term of supply agreement" } } }, "localname": "LicenseAgreementSupplyAgreementTerm", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails" ], "xbrltype": "durationItemType" }, "vcel_LicenseAgreementTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement [Text Block]", "label": "License Agreement [Text Block]", "terseLabel": "NexoBrid License and Supply Agreements" } } }, "localname": "LicenseAgreementTextBlock", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreements" ], "xbrltype": "textBlockItemType" }, "vcel_LongtermInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term Investments [Member]", "label": "Long-term Investments [Member]", "terseLabel": "Long-term investments" } } }, "localname": "LongtermInvestmentsMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/InvestmentsDetails" ], "xbrltype": "domainItemType" }, "vcel_MACIImplantsAndKitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MACI Implants And Kits", "label": "MACI Implants And Kits [Member]", "terseLabel": "M A C I Implants and kits" } } }, "localname": "MACIImplantsAndKitsMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_MediWoundLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "MediWound Ltd [Member]", "label": "MediWound Ltd [Member]", "terseLabel": "MediWound Ltd" } } }, "localname": "MediWoundLtdMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/NexoBridLicenseandSupplyAgreementsDetails", "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "domainItemType" }, "vcel_NexoBridMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NexoBrid", "label": "NexoBrid [Member]", "verboseLabel": "NexoBrid" } } }, "localname": "NexoBridMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_NumberOfContractedSpecialtyPharmacies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Contracted Specialty Pharmacies", "label": "Number of Contracted Specialty Pharmacies", "terseLabel": "Number of specialty pharmacies" } } }, "localname": "NumberOfContractedSpecialtyPharmacies", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "integerItemType" }, "vcel_NumberOfProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Products", "label": "Number Of Products", "terseLabel": "Number of commercial-stage products" } } }, "localname": "NumberOfProducts", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/OrganizationDetails" ], "xbrltype": "integerItemType" }, "vcel_ProviderorFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Provider or Facility [Member]", "label": "Provider or Facility [Member]", "terseLabel": "Provider or Facility" } } }, "localname": "ProviderorFacilityMember", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueSummaryofDisaggregationofRevenueDetails" ], "xbrltype": "domainItemType" }, "vcel_RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable", "label": "Restricted Stock Held For Employee Tax Remittance Included In Accounts Payable", "terseLabel": "Restricted stock held for employee tax remittance included in accounts payable" } } }, "localname": "RestrictedStockHeldForEmployeeTaxRemittanceIncludedInAccountsPayable", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vcel_RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage", "label": "Revenue, Revenue Recognized, Change in Uncollectible Analysis, Percentage", "terseLabel": "Change in estimate of uncollectible (percent)" } } }, "localname": "RevenueRevenueRecognizedChangeinUncollectibleAnalysisPercentage", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "percentItemType" }, "vcel_RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount", "label": "Revenue, Revenue Recognized, Effect Of 0.5% Change In The Estimated Uncollectible Percentage, Amount", "terseLabel": "Change in revenue recognized due to 0.5% change in uncollectible percentage" } } }, "localname": "RevenueRevenueRecognizedEffectOf0.5ChangeInTheEstimatedUncollectiblePercentageAmount", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "vcel_RightOfUseAsset": { "auth_ref": [], "calculation": { "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Right Of Use Asset", "label": "Right Of Use Asset", "totalLabel": "Total leased assets" } } }, "localname": "RightOfUseAsset", "nsuri": "http://vcel.com/20230331", "presentation": [ "http://vcel.com/role/LeasesSummaryofassetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1)(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e777-108305", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(d)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r524": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "https://asc.fasb.org/topic&trid=2122208", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 64 0001628280-23-017039-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-017039-xbrl.zip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